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Summary 
The Angiopoietin/Tie system is one of the most important vascular-tissue specific signaling pathways, 
essential during embryonic vascular development and maturation, and key regulator of adult 
homeostasis. The Tie receptors, Tie1 and Tie2, and their secreted angiopoietin (Ang) ligands, Ang1 and 
Ang2, have been identified as the main factors of the system. Ang1 is primarily produced by perivascular 
cells and acts in a paracrine fashion as strong Tie2 agonist that mediates endothelial cell (EC) survival and 
maturation signals. Ang2, expressed and stored in EC, functions primarily as an antagonist of Tie2 and 
promotes vascular destabilization. Nevertheless, it can act as a partial agonist of Tie2 in a context-
dependent manner.  Tie1 and Tie2 are both expressed by EC and share high similarities in their overall 
domain structure. Whereas Tie2 acts as the primary signal transducing receptor, Tie1 function as a 
holoreceptor is not completely understood: It does not activate signaling pathways on its own but rather 
modulates the Tie2 kinase activity. Tie1 is highly expressed in activated endothelial cells during 
embryogenesis and during pathological conditions, such as tumor progression and metastasis, but it is 
downregulated in the adult quiescent endothelium. Thus, Tie1 global deficiency in mice leads to 
embryonic lethality at late gestation due to perturbed vessel integrity, while its specific deletion in the 
growing tumor vasculature results in decreased blood vessel density. The combination of high expression 
in the tumor endothelium and low expression in the adult vasculature makes Tie1 an interesting 
molecule and a potential therapeutic target.  
Angiogenesis is one of the most critical steps during tumor growth and metastasis progression. 
Comparative tumor and metastasis experiments in wildtype and Tie1 endothelial-deficient mice were 
performed to mechanistically unravel the role of the orphan receptor during individual steps of tumor 
progression and metastasis. Analysis of the tumor vasculature demonstrated that Tie1 endothelial 
deletion induces no significant changes in the early steps of tumor growth but rather affects later steps 
of tumor progression. Endothelial-Tie1 deletion induces progressively normalization of primary tumor 
blood vessels accompanied by decreased microvessel density, increased mural cell coverage, improved 
vessel perfusion and reduced tumor cell intravasation into the blood stream as well as extravasation at 
secondary sites. These effects result in almost complete inhibition of post-surgical spontaneous lung 
metastasis and improved overall survival of Tie1-endothelial deleted mice. Mechanistically, Tie1 
targeting in the primary tumor leads to vascular normalization and stabilization by increasing the 
proportion of Tie2-positive endothelial cells (stalk cells) and by potentiating the Ang1/Tie2 signaling axis 
which is primarily essential for the maintenance of endothelial quiescence and survival.  
The data establish a remarkable contribution of the orphan receptor Tie1 to primary tumor angiogenesis 
and to individual steps of metastatic cascade. These findings contribute to the mechanism-guided 
validation of Tie1 as a therapeutic target to sharpen the balance between triggering vascular regression 
and promoting vascular normalization. 
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Zusammenfassung 
Das Angiopoietin/Tie-System ist einer der wichtigsten Gefäß-spezifischen Signalwege. Es ist essentiell 
während der embryonalen Gefäßentwicklung und reifung, und ist ein wesentlicher Regulator der 
Homöostase im Erwachsenen. Die Tie-Rezeptoren, Tie1 und Tie2, und ihre sezernierten Angiopoetin 
(Ang)- Liganden, Ang1 und Ang2, wurden als Hauptfaktoren des Systems identifiziert. Ang1 wird primär 
von perivaskulären Zellen produziert und wirkt in parakriner Weise als starker Tie2-Agonist, der Endothel 
zellen Überlebens- und Reifungssignale vermittelt. Ang2 wird von Endothel zellen exprimiert und 
gespeichert und wirkt vorrangig als Antagonist des Tie2-Signalweges, der so eine Gefäßdestabilisierung 
fördert. Allerdings wirkt Ang2 kontextabhängig teilweise auch als Agonist. Tie1 und Tie2 werden beide 
von Endothel zellen exprimiert und haben hochgradige Ähnlichkeiten in ihrer Proteinstruktur. Während 
Tie2 den eigentlichen Signaltransduktionsrezeptor darstellt, ist die Funktion von Tie1 als Holorezeptor 
noch nicht vollständig geklärt: Nach dem heutigen Wissensstand aktiviert es selbst nicht direkt 
Signalwege, sondern interagiert und moduliert die Tie2-Kinase-Aktivität. Tie1 wird in aktivierten 
Endothel zellen während der Embryogenese und bei pathologischen Zuständen wie der Tumor 
progression und Metastasierung stark exprimiert, während der Expressionsstand im erwachsenen, 
ruhenden Endothel eher niedrig ist. Somit führt eine Tie1-Deletion in Mäusen zu embryonaler Letalität 
im späteren Trächtigkeitsstadium aufgrund der gestörten Gefäßintegrität. Eine spezifische Deletion von 
Tie1 im wachsenden Tumorendothel führt zu einer verminderten Blutgefäßdichte. Die Kombination einer 
erhöhten Expression im Tumorendothel und geringer Expression in den ruhenden Gefäßen macht Tie1 zu 
einem interessanten Molekül als potentielles therapeutisches Medikament. 
Die Angiogenese ist eine der kritischsten Schritte während des Tumorwachstums und der Metastasen-
Progression. Vergleichende Tumor- und Metastasenexperimente in Wildtyp- und endothelspezifischen 
Tie1-defizienten Mäusen wurden durchgeführt, um die Rolle des Orphan-Rezeptors Tie1 während 
einzelner Schritte der Tumor progression und Metastasenbildung mechanistisch zu entschlüsseln. Die 
Analyse der Tumorgefäße zeigte, dass eine endotheliale Tie1 Deletion keine signifikanten Veränderungen 
in den frühen Stadien des Tumorwachstums induziert, sondern eher die späteren Stadien der Tumor 
progression beeinflusst. Endothelspezifische Tie1-Deletion induzierte eine fortschreitende 
Gefäßnormalisierung der Blutgefäße im Primärtumor, begleitet von einer verminderten Gefäßdichte, 
einer erhöhten periendothelialen Gefäßabdeckung, einer verbesserten Gefäßperfusion, einer 
reduzierten Tumorzellintravasation in den Blutstrom sowie einer Extravasation an sekundären 
Positionen. Diese Effekte führten zu einer nahezu vollständigen Hemmung spontaner Lungenmetastasen 
nachdem der Tumor operativ entfernt wurde und einem verbesserten Gesamtüberleben in den Tie1-
endothelial-deletierten Mäusen. Mechanistisch gesehen führt das Tie1-Targeting im Primärtumor zu 
einer vaskulären Normalisierung und Stabilisierung durch eine Erhöhung des Anteils an Tie2-positiven 
Endothel zellen (Stalkzellen) und dadurch zu einer Verstärkung der Ang1/Tie2-Signalachse, die primär für 
die Aufrechterhaltung des ruhenden Endothels und dessen Überleben von wesentlicher Bedeutung sind. 
Zusammenfassung  
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Die Daten erbringen einen bedeutenden Beitrag des Orphan Rezeptors Tie1 zur primären 
Tumorangiogenese und noch wesentlicher zu seiner Rolle in den einzelnen Schritten der metastatischen 
Kaskade. Diese Erkenntnisse tragen entscheidend zu einer Mechanismus-geführten Validierung von Tie1 
als therapeutisches Target bei, das das Gleichgewicht zwischen Gefäßregression und der vaskulären 
Normalisierung fördern kann. 
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1. Introduction 
1.1 Cancer Statistics 
Tumorigenesis is a multi-step process characterized by genetic alterations that drive the progressive 
transformation of normal human cells into highly malignant derivatives (Foulds, 1954). This process is 
formally analogous to Darwinian evolution, in which the succession of genetic changes confers growth 
advantage, leading to the progressive conversion of normal cells into cancer cells (Foulds, 1954; Nowell, 
1976). Nevertheless, tumors are more than insular masses of proliferating cancer cells; they are complex 
tissues composed of multiple distinct cell types that participate in heterotypic interactions between each 
other. This notion reveals that the biology of tumors must also encompass the contributions of the 
“tumor microenvironment” to tumorigenesis (Hanahan and Weinberg, 2011). As reported by the World 
Health Organization (WHO), cancer is one of the most prominent causes of mortality worldwide, with 8.2 
million deaths from cancer (13% worldwide) and 14 million people affected every year. In the next two 
decades, 23.6 million cancer cases are expected (http://www.who.int/cancer/en/). The most common 
causes of cancer death in men are lung, prostate, colorectal, stomach and liver cancer. On the contrary, 
the most prevalent in women are colorectal, lung, breast, stomach and cervical cancer. A recent review 
of the fifth version of GLOBOCAN, the source of cancer incidence and mortality from 184 countries 
worldwide, indicated lung, breast, and colorectal cancer as the most commonly diagnosed cancers, while 
estimating lung, liver and stomach cancer as the most common causes of death (Ferlay et al., 2015). 
Although much progress has been made in the last decades against cancer, the overall incidence and 
mortality of cancer is estimated to rise to 12 million cancer deaths in 2030 (Fig. 1). 
Global projections for selected causes, 2004 to 2030 
 
 
Figure 1: Global projections for selected causes, 2004 to 2030 
 The cancer mortality will dramatically increase in the following years. Taken from WHO, global burden of disease 
2004, http://www.who.int/topics/global_burden_of_disease/en/). 
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Notably, cancer-related deaths are generally not caused by the primary tumor, rather than by the spread 
of tumor cells throughout the body, a process known as metastasis (Steeg, 2016). The diagnosis of 
metastatic disease indicates a terminal illness and causes approximately 90% of the human cancer 
deaths (Mehlen and Puisieux, 2006; Wirtz et al., 2011). 
1.2 Cancer Progression 
Cancer types are classified according to their site of origin: carcinomas have epithelial origin, sarcomas 
derive from connective tissue, leukemias and other hematological malignancies derive from blood-
forming tissues, lymphomas originate from cells of the lymphatic immune system and myelomas arise 
from plasma cells. Albeit their different origins, all types of cancers share common essential alterations 
in the cell physiology that collectively dictate the malignant phenotype (Hanahan and Weinberg, 2011). 
This set of features is known as “hallmarks of cancer” and was first described by Hanahan and Weinberg 
in 2000. These characteristics include self-sufficiency in growth signals, insensitivity to anti-growth 
signals, ability to evade apoptosis, limitless replicative potential, sustained angiogenesis, and tissue 
invasion and metastasis (Fig. 2) (Hanahan and Weinberg, 2000). 
 
Figure 2: The Hallmarks of cancer 
Reprinted with permission from (Hanahan and Weinberg, 2011). Cancer cells acquire a) six functional capabilities 
enhancing their tumorigenic performance; b) New emerging hallmarks and two additional enabling characteristics.  
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Recently, new emerging hallmarks have been added such as reprogramming energy metabolism, evading 
immune surveillance, tumor promoting inflammation, and genome instability and mutation (Hanahan 
and Weinberg, 2011). 
1.3 Metastatic dissemination of cancer: the metastatic cascade 
Activating invasion and metastasis has been proposed as a hallmark of cancer already in the last decade 
(Hanahan and Weinberg, 2000). The term metastasis derives from the Greek words μετά+ στάσις; where 
(μετά), meta, means “next” and στάσις (stasis), “placement”. Therefore, metastasis means displacement 
and it represents a multistep process during which malignant cells disseminate from the tumor of origin 
to distant organs. It is the third most diffuse cause of mortality and the first cause of cancer morbidity 
and death (Mehlen and Puisieux, 2006; Wirtz et al., 2011). Although much progress has been made over 
the last years in order to understand the mechanism of cancer biology, new efforts are needed in cancer 
research to decipher the advanced stages of metastatic progression. Indeed, given the high incidence in 
the populations and the grave prognosis, new therapies are required to combat cancer. 
In 1889, Stephen Paget’s proposed that metastasis depends on cross-talk between selected cancer cells 
(“seeds”) and specific organ microenvironment (“soil”), where the dependence of the seed on the soil is 
essential (Paget, 1989). In 1929, James Ewing challenged Paget’s theory, claiming that metastatic 
dissemination occurs by purely mechanical factors that result from the anatomical structure of the 
vascular system (Fidler, 2003). Nowadays, metastatic progression is considered as a multistage event, 
critically dependent on the interaction of metastasizing cells with their microenvironment, either at the 
primary tumor site or at the site of metastasis. To be able to develop metastasis, cancer cells need to i) 
acquire motility and invade locally into the tumor adjacent tissue, ii) intravasate into blood vessels and 
lymphatic, iii) survive in the circulation, iv) extravasate into target organs, and v) colonize the tissue, 
supported by angiogenesis and micro-/macro-metastasis development (Fidler, 2003; Pantel and 
Brakenhoff, 2004) (Fig. 3).  
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Figure 3: Schematic representation of the different steps of the metastatic cascade 
a) Growth of tumor cells is progressive: in the beginning, neoplastic cells receive oxygen and supplies via diffusion 
from the host vasculature. b) When the tumor mass exceeds 1-2 mm in diameter, tumor cells start producing and 
releasing angiogenic factors that stimulate extensive tumor vascularization, important either for the delivery of 
oxygen and nutrients, and for the elimination of metabolic waste. c) Tumor cells either detach from each other or 
form small clusters, and then invade the surrounding tissue, reaching the blood or lymphatic capillaries and 
intravasating through the endothelial layer. d) In the circulation tumor cells encounter many difficulties and try to 
escape the immune system from being cleared out, so only few cells survive and reach capillary beds of distant 
organs. e) Here they attach to the inner vessel wall and extravasate into surrounding tissue. Once successfully 
transmigrated in the organ, the majority of tumor cells die while a small proportion stay in a non-proliferative 
“dormant state”. f) Tumor cells proliferation and formation of metastatic colonies are the last steps of metastatic 
cascade.  
1.3.1 Invasion 
To metastasize to other organs, tumor cells need to migrate out from the primary tumor site. This 
motility is obtained either by the loss of cell adhesion or by an increase in factors that are involved in the 
degradation of the extracellular matrix (ECM). In particular, tumor cells need to lose cell-cell contacts, to 
anchor to the ECM and secrete metalloproteinases in order to cut the ECM and migrate through it, 
according to the gradient formed by the chemokines released from ECM degradation (Liotta, 1986). The 
gain of migratory capabilities requires a temporary and reversible phenomenon that is known as 
epithelial to mesenchymal transition (EMT) (Thiery, 2009). Because of their epithelial origin, carcinoma 
cells are originally non-motile cells, presenting tight cell-cell interaction and basal-apical polarization. 
During EMT, tumor cells lose their rigid epithelial morphology and transform in motile spindle-like 
mesenchymal morphology. This transition requires fundamental changes at the transcriptional level; for 
example, cell-cell adhesions are disrupted by repression of E-Cadherin and cytokeratin expression, while 
the expression of typical components of the mesenchymal cytoskeleton is induced, such as vimentin and 
 smooth muscle actin (SMA). In addition, cell-basement membrane adhesions are reduced by 
downregulation of some integrins, whereas disseminating tumor cells start expressing typical fibroblast 
markers, such as  N-cadherin, fibronectin and collagen type I (Hanahan and Weinberg, 2011). 
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Molecularly, EMT can be induced by various growth factors that are secreted in the tumor 
microenvironment like TGFβ (transforming growth factor β), HGF (hepatocyte growth factor), IGF 
(insulin-like growth factors), some members of the epidermal growth factors (EGF) and fibroblast growth 
factors (FGF). All these different upstream molecules converge in the same signaling pathways that 
involve the small GTPases RhoA and Rac1 (Ras-related C3 botulinum toxin substrate 1), Ras (Rat 
Sarcoma), PI3K (phosphoinositol-3 kinase), MAPK (mitogen-activated protein kinase), ILK (integrin-linked 
kinase) and the Jagged/Notch pathway (Thiery, 2002). The EMT transdifferentiation is limited to a 
restricted number of single cells at the invasive front: intravital imaging analysis has shown that just 1-
5% of tumor cells display motile capabilities (Sahai, 2005). The acquired mesenchymal phenotype is 
reversible once disseminating tumor cells reach secondary sites and form metastases. Here, cells 
undergo the mesenchymal to epithelial transition (MET), whereby they lose their motile and spindle-like 
shape and regain a rigid epithelial phenotype to form solid epithelial-looking metastasis (Hugo et al., 
2007; Tsai and Yang, 2013).  
Besides EMT, tumor cells can invade distant tissues through collective cell migration. In this process 
tumor cells move in concert, without completely disrupting their cell-cell contacts, and express 
podoplanin at their site of invasion (McCaffrey et al., 2012; Wicki et al., 2006). Recently, the structural 
organization of the ECM has also been found to be involved in the tumor cell invasion. Rearrangement of 
collagen into a more linearized shape promotes tumor cell invasion, while a non-linearized and less stiff 
fibrillary collagen can impede tumor cell motility (Maller et al., 2013). In conclusion, tumor cells invasion 
can be initiated by different processes that induce changes in tumor and stroma cells, in order to 
remodel and restructure the ECM.  
1.3.2 Intravasation 
Intravasation occurs shortly after the successful invasion of tumor cells through the basement 
membrane and ECM, and refers to the process through which tumor cells enter the blood stream within 
or close to the primary tumor site. This is the rate-limiting event for tumor cells to give rise to distant 
metastasis or not. Intravasation requires the disruption of endothelial junctions for cancer cells to cross 
the endothelium, in a process known as transendothelial migration. Indeed, the newly formed tumor 
blood vessels generally present weak cell-cell junctions, that can be easily crossed by tumor cells to enter 
the blood stream (Weis and Cheresh, 2011).  
It is still not clear if intravasation is a passive or an active mechanism. On one hand, it has been shown 
that a notable number of tumor cells shed through immature tumor vasculature and that a correlation 
exists between the number of large vessels diameter with the amount of tumor cells clumps (Butler and 
Gullino, 1975; Liotta et al., 1976), supporting the passive form of intravasation. On the other hand, the 
high production of tumor-cell intrinsic factors or factors produced by the stroma gives significant 
evidence for an active mechanism. For example, matrix metalloproteinases 1 (MMP1) is required for 
intravasation of tumor cells through the endothelial monolayer, via activating the protease-activated 
receptor 1 (PAR1), that mediates cytoskeleton rearrangements and remodeling of endothelial junctions 
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(Juncker-Jensen et al., 2013). Alternatively, a disintegrin and metalloproteinase 12 (ADAM12) on 
endothelial cells (EC) can induce cleavage of vascular-endothelial cadherin (VE-cadherin) and Tie2, 
causing the disruption of endothelial junctions (Frohlich et al., 2013). Notch signaling has also been 
postulated to contribute to intravasation: Notch receptor on tumor cells can bind to Notch ligands on EC 
and promote transmigration through the endothelial junctions (Sonoshita et al., 2011).  
Moreover, cancer cells invasion through the stroma to the blood vessels can be promoted by tumor 
associated macrophages (TAM). They can attract neoplastic cells towards blood vessels by releasing EGF 
(Roussos et al., 2011; Wyckoff et al., 2004; Wyckoff et al., 2007) and tumor necrosis factor 1 (TNF1) 
(Reymond et al., 2013), which induce the retraction of endothelial junctions, thus facilitating 
transendothelial migration. Promotion of vessel leakiness is another mechanism through which 
macrophages induce intravasation (Mierke, 2012). TAM have also been associated with increased 
hypoxia (Rezvani et al., 2011); generally the hypoxic microenvironment mediates the activation of 
pathways correlated to ECM remodeling, therefore impacting tumor cell transmigration.  
In conclusion, intravasation into the blood stream is a complicated process that involves different cell 
types besides tumor cells. New tools and new in vitro assays are needed in order to better recapitulate 
the in vivo scenario, making it possible a clear comprehension of this process. 
1.3.3 Survival in the circulation  
Once into the blood stream, tumor cells are exposed to continuous stress, such as shear stress, absence 
of cell contacts or of ECM and immune surveillance. To successfully extravasate and colonize secondary 
sites, tumor cells need to overcome these obstacles. This explains the disparity between the millions of 
cells shed from a tumor every day and the relatively few clinically detectable metastases (Bockhorn et 
al., 2007; Cristofanilli, 2006). A notable amount of tumor cells, for example, undergoes apoptosis in the 
circulation induced by shear stress, and a significant number of cells are already apoptotic into the 
primary tumor but undergo passive shedding, without the involvement of active cell migration (Bockhorn 
et al., 2007). Tumor cells are protected by platelets against physical stress in the circulation and against 
lysis induced by cytotoxic immune cells (Labelle et al., 2011; Nieswandt et al., 1999). In order to improve 
their viability in the blood stream, tumor cells migrate in clusters (Duda et al., 2010). These clusters 
express plakoglobin, an epithelial cell junction molecule, that if inhibited can prevent metastasis (Aceto 
et al., 2014). Via interaction between selectin and glycoproteins, tumor cells can also acquire a rolling 
behavior on the inner surface of the blood vessels (Dimitroff et al., 2004). In particular, the integrins 
expressed on the surface of tumor cells bind to adhesion molecules on the EC surface, forming stable 
interactions. This event is crucial for subsequent extravasation and metastatic colonization (Garofalo et 
al., 1995).  
1.3.4 Extravasation  
Extravasation is an essential and rate-limiting process for metastatic spread. Shedded tumor cells 
transmigrate through the endothelium into distant organs in a way that is far less efficient if compared 
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to leukocytes extravasation: while the latter can reach secondary tissues in order of minutes, tumor cells 
can take up to 1-2 days (Strell and Entschladen, 2008). During extravasation, tumor cells start producing 
adhesion molecules, like CD44, integrins and galectin-3 (Hiratsuka et al., 2011; Miles et al., 2008; 
Murugaesu et al., 2014), promoting a direct contact with endothelial cells, and start secreting vasoactive 
compounds such as vascular endothelial growth factor (VEGF), angiopoietin-like 4 (Angptl4), HGF, 
angiopoietin 2 (Ang2), chemokine (C-C motif) ligand 2 (CCL2), stromal cell-derived factor1 (SDF1) that 
induce vascular permeability or loosening of endothelial junctions, therefore favoring metastasis 
(Balkwill, 2012; Garcia-Roman and Zentella-Dehesa, 2013). ATP, released by tumor cell-activated 
platelets, is also an important factor that facilitates opening of endothelial barrier and therefore tumor 
cell extravasation (Schumacher et al., 2013). Clinical data have shown that high platelet counts in breast 
cancer patients associate with poor survival prognosis (Taucher et al., 2003). Another mechanism 
through which tumor cells promote extravasation is the production of substances that cause endothelial 
damage, such as reactive oxygen species (ROS), epiregulin, cyclooxygenase 2, MMPs etc (Gupta et al., 
2007). In conclusion, the process of extravasation requires production and release in the 
microenvironment of new factors by tumor cells and their physical interaction with the endothelium. 
1.3.5 Dormancy and survival at the secondary site 
Once successfully transmigrated to a secondary site, tumor cells either die or stay in a viable but non-
proliferative state, called “dormancy”. For the patients, this results in disease free-periods that can last 
even for 20-25 years, during which they do not develop metastasis (Ghajar et al., 2013; Karrison et al., 
1999). Although dormancy is a status that frequently occurs in breast cancer, there is no detailed 
knowledge about the signals that induce tumor cells to transition from a dormant state to a proliferating 
state and vice versa. Studies have suggested that a large number of solitary cells that arrive at secondary 
site and fail to initiate cell division can survive for a long period of time in the organ. This pause in 
progression is partially due to the immortalization of disseminated cancer cells, acquired after gradual 
accumulation of mutations that induce loss of p53, retinoblastoma 1 (Rb1), cyclin-dependent kinase 
inhibitor 2a (p16), activation of RAS, BRAF and amplification of ERBB2 (Hanahan and Weinberg, 2000). 
Alternatively, it has been suggested that pre-angiogenic micro-metastases remain dormant because the 
tumor cell proliferation is balanced by an equivalent rate of cell death (Hahnfeldt et al., 1999; Holmgren 
et al., 1995). In conclusion, disseminated cells in micro-metastases or individual cells need to survive 
during this period of dormancy. The microenvironment can play an essential role in surveilling the 
growth of the lesions (Bragado et al., 2012). 
1.3.6 Colonization and metastatic outgrowth 
To successfully complete the metastatic cascade, extravasated tumor cells need to proliferate and to 
form metastatic colonies. As suggested by Paget with the “seed and soil” theory, tumor cells can only 
grow in a suitable microenvironment (Paget, 1989). Nevertheless, it is still not clear if the primary tumor 
releases factors that facilitate the formation of a pre-metastatic niche where tumor cells can seed, or if 
shedded tumor cells produce factors that remodel the microenvironment in secondary sites according to 
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their needs. Evidence has been provided that the primary tumor releases metalloproteinases 9 (MMP9) 
or other enzymes, such as lysyl oxidase (LOX), which can either act on endothelial cells of secondary sites 
(Kaplan et al., 2006) or induce recruitment of macrophages to distant organs (Erler et al., 2009), thereby 
promoting colonization. Tumor cells proliferation in the metastatic site occurs after activation of kinases 
such as focal adhesion kinase (FAK) and the extracellular signal regulated kinase (ERK) (Aguirre Ghiso et 
al., 1999), and it is driven by the formation of filopodia-like protrusions (Shibue et al., 2012). Recent work 
has also shown a role of exosome in the pre-metastatic niche formation (Costa-Silva et al., 2015). In 
conclusion, suitable tumor microenvironment is essential for tumor formation, progression and 
metastatic outgrowth.  
1.4 The tumor microenvironment  
The tumor microenvironment, also known as tumor stroma, surrounds the cancer cells and dynamically 
interacts with them, promoting primary tumor initiation, supporting cancer progression and endorsing 
metastatic outgrowth (Li et al., 2007; Pietras and Ostman, 2010). Tumor stroma is composed of ECM and 
other non-malignant cell types such as inflammatory cells, stromal myofibroblasts, cellular constituent of 
blood and lymphatic vessels such as endothelial cells, pericytes and smooth muscle cells (SMC) (Gerhardt 
and Semb, 2008; Pietras and Ostman, 2010; Sund and Kalluri, 2009; Wels et al., 2008). Tumor growth 
strictly depends on its vasculature, which provides the delivery of oxygen and supplies into the 
microenvironment. Tumor initiates as an avascular mass, where cancer cells grow along pre-existing 
vessels in order to satisfy their need of metabolites. When tumor outgrows the supplies, it triggers the 
“angiogenic switch” that induces the formation of a vascular network to secure tumor cell proliferation 
and growth (Folkman, 1971; Nyberg et al., 2008). 
1.4.1 Vascular components  
The vascular system controls the metabolic exchange between the blood and adjacent tissues, 
guaranteeing a constant delivery of oxygen and supplies. It is composed of EC and mesenchymal derived 
cells, such as pericytes and smooth muscle cells, surrounded by a basement membrane (BM). EC derive 
from hemangioblasts and/or angioblasts (Augustin et al., 1994; Coultas et al., 2005). They line together 
forming a monolayer along the inner vessel wall, creating a lumen that allows the passage of the blood. 
Blood vessels can have different size: capillaries, arterioles and venules are small vessels, while arteries 
and veins are large vessels. Smaller vessels are surrounded by the basal lamina and are covered by single 
pericytes. In the larger vessels, the endothelium is covered by a dense layer of SMC and pericytes that 
are essential for vessel stabilization (Fig. 4). 
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Figure 4: The vascular system 
The hierarchical structure of the blood vascular system consists of arteries-arterioles-capillaries-venules-veins. 
Arterioles, capillaries and venules are surrounded by basal lamina and are loosely covered by perivascular cells. 
Larger vessels, such as arteries and veins, are densely covered by SMC and pericytes, in order to increase blood 
vessel elasticity, therefore promoting blood flow.  
 
There are differences also between arteries and veins: the former have a thick and elastic endothelial 
wall in order to sustain the high blood pressure coming from the heart to distant organs; while the latter 
present a thinner wall and are less covered by mural cells (Aird, 2007a; Aird, 2007b; Garlanda and 
Dejana, 1997).  
1.4.2 Tumor-vascular interaction  
The diffusion limit for oxygen is 100-150 m. Therefore, tumor cells need to be within a distance of 
maximum 200 m from a functional vessel to survive (Torres Filho et al., 1994). When the 
microenvironment becomes hypoxic, tumor cells release pro-angiogenic factors like VEGF and platelet-
derived growth factor (PDGF), which favor neovascularization via induction of the angiogenic switch. 
Nevertheless, the tumor microenvironment is also characterized by anti-angiogenic cytokines such as 
thrombospondin 1 (TSP1), angiostatin and endostatin, which inhibit angiogenesis, causing hypoxia in the 
tumor microenvironment, and lead to tumor cells death. The balance between pro- and anti-angiogenic 
molecules is controlled by different pathways. In particular, it has been demonstrated that RAS 
activation upregulates VEGF, while downregulating the angiogenesis inhibitor TSP1 (Rak et al., 1995; 
Sheibani and Frazier, 1996). On the contrary, p53, phosphatase and tensin homolog (PTEN) and mothers 
against decapentaplegic homolog 4 (SMAD4) have been shown to induce expression of TSP1 
(Chandrasekaran et al., 2000; Dameron et al., 1994; Volpert et al., 1997). The direct or indirect 
interactions between cancer cells and endothelial cells can be rate-limiting for tumor growth.  
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1.5 Angiogenesis and blood vessel formation  
Angiogenesis is the formation of new blood vessels from pre-existing ones and it differs from 
vasculogenesis, which is the process where blood vessels form de novo. The angiogenic cascade is a 
tightly regulated event composed of several steps, such as activation of endothelial cells by pro-
angiogenic stimuli, degradation of the basal lamina, proliferation and migration of endothelial cells, 
lumen formation and recruitment of mural cells to stabilize the newly formed blood vessels (Risau, 
1997). In particular, during hypoxic condition, hypoxia inducible factor 1 (HIF1) is activated in 
endothelial cells, resulting in the expression of VEGF-A and its receptor (VEGFR2) (Tang et al., 2004). The 
production and release of VEGF-A create a gradient that is followed by endothelial cells in order to reach 
avascular areas and create new vessel sprouts. This occurs via tip cells formation and subsequent 
proliferation of the adjacent stalk cells (Gerhardt and Betsholtz, 2003; Ruhrberg et al., 2002). 
Subsequently, ECM and the basement membrane are degraded by activated metalloproteinases, 
allowing mural cells to migrate on the top of the blood vessels and proliferate (Folkman and D'Amore, 
1996; Hughes, 2008). The interaction between EC and perivascular cells further promotes endothelial 
quiescence, via inducing expression of MMP inhibitors, so that ECM degradation is suppressed (Beck and 
D'Amore, 1997; Benjamin et al., 1998; Saunders et al., 2006).  
During tumor growth, the demand for oxygen and nutrients and the need to eliminate metabolic waste 
from the tumor microenvironment induces a continuous release of proangiogenic molecules that foster 
the production of abnormal tumor vessels in their appearance and function (Baluk et al., 2005; Folkman, 
1971; Jain, 2005; Nagy et al., 2010). Tumor vessels lose their hierarchical structure (arterioles-capillaries-
venules-veins) and appear tortuous, disorganized, hyperpermeable and poorly functional. EC, indeed, 
lose their typical cobblestone shape and present loose interconnections, becoming occasionally 
multilayered. Mural cells are poorly attached to the EC, favoring a reduction in blood vessel functionality 
and an increase in permeability. This chaotic vasculature, therefore, leads again to insufficient supply of 
nutrients, oxygen and growth factors to the tumor mass, and re-stimulates the release of proangiogenic 
molecules, exacerbating the scenario (Goel et al., 2011; Jain, 2005). The hypoxic and acidic milieu that 
results from this non-productive angiogenesis, implies limitations in drug delivery and lowers the efficacy 
of radiotherapy (Vaupel et al., 2001). 
1.5.1 Sprouting angiogenesis 
Although there are several processes leading to angiogenesis, sprouting angiogenesis plays a major role 
during tumor blood vessels formation. This process has been studied in great detail, allowing the 
development of drugs that selectively target this mechanism. As mentioned before, sprouting 
angiogenesis involves degradation of the ECM and basement membrane to facilitate the migration of 
endothelial tip cells towards a gradient of proangiogenic stimuli. Two major signaling pathways 
orchestrate sprouting angiogenesis: VEGF-VEGFR and DLL4-Notch pathway (Hellstrom et al., 2007; Phng 
and Gerhardt, 2009; Suchting et al., 2007). VEGF act through three structurally related VEGF receptor 
tyrosine kinases, denoted VEGFR1 (Flt1), VEGFR2 (Flk1) and VEGFR3 (Flt). Binding of VEGF to its VEGFR2 
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or VEGFR3 induces receptor auto- or transphosphorylation and therefore activation of a signaling 
cascade that is involved in endothelial cell proliferation and migration. VEGFR1 is a decoy receptor, with 
weak kinase activity. It is highly expressed in stalk cells and it negatively regulates VEGFR-2 response 
(Koch and Claesson-Welsh, 2012). Dll4 is a Notch ligand, upregulated in tumor endothelial tip cells by 
VEGF (Claxton and Fruttiger, 2004; Liu et al., 2003). Dll4 induces expression of Notch in the adjacent stalk 
cells, which downregulate VEGFR2, upregulate VEGFR1, and do not respond anymore to VEGF stimuli, 
leading to a failure of sprouting in the stalk cell compartment. Interference with the Dll4-Notch 
expression could lead to hypersprouting, resulting in a non-perfused, chaotic and non-functional 
vasculature (Noguera-Troise et al., 2006; Ridgway et al., 2006; Scehnet et al., 2007). In opposition, the 
other Notch ligand, Jagged1 (Jag1), has proangiogenic functions and it is expressed either by tumor 
endothelial cells or by cancer cells.  
1.5.2 Vascular cooption 
Several mechanisms contribute to tumor angiogenesis. Amongst these, vascular cooption is an 
angiogenic process that occurs during the early stages of tumor growth. In this mechanism, tumors 
obtain a blood supply by hijacking the existing vasculature, and tumor cells proliferate along the vessels 
of the host organ until the tumor milieu becomes hypoxic and induces the angiogenic switch. This 
phenomenon is observed in highly vascularized organs, such as lungs and brain (Donnem et al., 2013). 
Ang2 has been proposed as a critical mediator of vessel cooption since its expression is induced in the 
endothelium of coopted tumor vessels as well as in the late stage tumors (Holash et al., 1999). 
Contrarily, VEGF is highly induced only in late stage angiogenic tumors (Holash et al., 1999). 
1.5.3 Intussusception 
Intussusception is a mechanism wherein a pre-existing vessel splits into two daughter vessels, via 
formation of a trans-vascular bridge. In particular, two endothelial cells that are on opposite site of the 
lumen form “kissing contacts” resulting in a transluminal bridge. Therefore, there is a rearrangement of 
EC junctions and new perforations are formed (Burri et al., 2004). This variant of angiogenesis has been 
demonstrated in models of colon adenocarcinoma and breast cancer (Djonov et al., 2001; Patan et al., 
1996). Intussusception has been correlated with low levels of VEGF. This process, therefore, might occur 
in anti-VEGF resistant tumors as a consequence of sprouting angiogenesis inhibition (Djonov et al., 2001).  
1.5.4 Vascular mimicry  
During vascular mimicry, tumor cells physically rearrange and form tubular, vessel-like structures. Recent 
studies have demonstrated that this process is driven by differentiation of cancer stem cells in vascular 
cell types, in specific cancers such as leukemia (Shen et al., 2008), breast cancer (Bussolati et al., 2009), 
ovarian cancer (Alvero et al., 2009) and glioblastoma (Ricci-Vitiani et al., 2010; Wang et al., 2010a).  
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1.6 VEGF-VEGFR2 system as anti-angiogenic target 
The VEGF-VEGFR2 signaling axis is the most important pathway activated in the tumor 
microenvironment after the angiogenic switch. Therefore, several drugs targeting VEGF and its receptors 
have been developed. The use of a monoclonal antibody against VEGF successfully inhibited 
angiogenesis in several tumor models (Kim et al., 1993). Despite the promising results obtained in pre-
clinical settings (Brekken et al., 2000; Holash et al., 2002), the survival of patients treated with either the 
monoclonal anti-VEGF antibody (Bevacizumab) or with Receptor Tyrosine Kinase Inhibitors (RTKI), was 
prolonged just by a few months (Allegra et al., 2011; de Gramont et al., 2012; Wood et al., 2000). The 
first anti-VEGF monoclonal antibody approved by the Food and Drug Administration (FDA) was 
Bevacizumab (Avastin®), a humanized murine antibody, that specifically binds the VEGF-A isoform 
(Ferrara et al., 2004). Avastin® treatment created a transient “normalization window” characterized by 
increased perivascular coverage and improved vessel perfusion and oxygenation (Winkler et al., 2004). 
Owing to this vessel normalization effect, anti-VEGF therapy was combined with chemotherapy and 
radiotherapy in order to improve drug delivery (Jain, 2005). Indeed, combinations of chemotherapy and 
Avastin® in a primary tumor treatment line increased the survival of patients with metastatic colorectal 
cancer (Hurwitz et al., 2004) and advanced lung cancer (Sandler et al., 2006), and the progression free 
survival (PFS) of metastatic breast cancer patients (Miller et al., 2007). However, Bevacizumab treatment 
was not successful in less vascularized cancer types such as gastric cancer and metastatic pancreatic 
cancer (Kindler et al., 2010; Van Cutsem et al., 2009). The BEATRICE clinical trial stated the failure of 
Bevacizumab as an adjuvant treatment in patients with triple-negative breast cancer, although it 
underlines the importance of VEGFR2 plasma levels as a prognostic biomarker (Cameron et al., 2013). In 
addition to monoclonal antibodies, several RTK inhibitors have been developed and successfully used in 
pre-clinical and clinical trials: Sunitinib, which targets VEGFR1 and VEGFR3, PDGFR  and ß and c-KIT 
(Abrams et al., 2003), or Sorafenib, which targets VEGFR2 and VEGFR3, and PDGFR  and ß have shown 
successful results in breast cancer (Escudier et al., 2007), renal cancer patients (Escudier et al., 2007) and 
hepatocellular carcinoma (Llovet et al., 2008).  
Since VEGF is a molecule important for pathological as well as physiological angiogenesis, anti-angiogenic 
therapy is not restricted just to the tumor vessels, and it causes severe side effects such as cardiac 
defects, gastrointestinal perforation and venous thromboembolic events (Eskens and Verweij, 2006; 
Verheul and Pinedo, 2007). Given the frequent side effects associated to Bevacizumab therapy, FDA 
revoked its approval for breast cancer treatment in 2011 (Rose, 2011). In conclusion, the efficiency of the 
anti-angiogenic therapy depends mostly on the tumor type and on tumor-stage.  
1.6.1 Anti-angiogenic therapy and vessel normalization 
Tumor angiogenesis consists mostly of the production of an increased number of blood vessels to serve a 
growing mass. This process occurs in an uncontrolled way and the resultant vascular network is highly 
abnormal. Anatomically tumor vessels are dilated, tortuous, disorganized and highly permeable, with 
several branch points (Goel et al., 2011). Unlike the microvasculature of normal tissue, tumor 
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vasculature is characterized by areas in which the vessel density is high and areas where vessel density is 
reduced. At the cellular level, the EC in tumor vessels have an irregular disorganized morphology and are 
loosely connected to each other. In addition, perivascular cells, both pericytes and SMC, are loosely 
attached to the blood vessels or are completely absent, facilitating the movement of EC into the 
surrounding matrix to form new vessels, and increasing vessel permeability. 
As mentioned before, the first rationale of anti-angiogenic therapy was to induce profound vascular 
regression, starving tumors to death or rendering them dormant (Folkman, 1971). The clinical response 
to anti-VEGF monotherapy was quite limited and was unable to induce vascular regression to cause 
significant tumor shrinkage (Cobleigh et al., 2003; Yang et al., 2003). However, combination of anti-
angiogenic therapy with chemotherapy showed successful results due to the synergistic effects of the 
two therapeutic regimens (Jain, 2014). A non-maximal dose of anti-angiogenic drug induces 
normalization of the tumor vasculature, reverting the grossly abnormal structure and function towards a 
more normal state. This facilitates the delivery of chemotherapy and therefore ensures a better 
response to cytotoxic treatment (Jain, 2014).  
In conclusion, a judicious dose of anti-angiogenic therapy creates a “normalization window” where 
immature and dysfunctional blood vessels are pruned away, whereas those remaining are actively 
fortified. This strategy limits also the damages to normal tissue vasculature, while promoting the delivery 
of systemically administered cytotoxic compounds (Fig. 5).  
 
Figure 5: Schematic representation of normalization window 
Modified from R. Jain review (Jain, 2014). The efficacy of therapies that combine anti-angiogenic and 
chemotherapeutic drugs depends on the dose and the delivery of each drug. Under specific dose of anti-angiogenic 
agents, a “normalization window” occurs, in which the addition of a chemotherapeutic gives the best outcomes. In 
this short time frame, there is passive pruning of immature vessels and normalization of the remaining ones, 
without affecting normal tissue vasculature. Furthermore, cancer cells become more vulnerable to cytotoxic 
therapies. The use of high dose anti-angiogenic drugs leads to normal-tissue toxicity and excessive pruning that 
compromises blood vasculature so that the delivery of the cytotoxic drugs is limited.  
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1.6.2 Resistance to anti-angiogenic therapy 
The greatest challenge for anti-angiogenic therapy is that a large number of cancer patients are 
intrinsically refractory to anti-angiogenic drugs and respond minimally or do not respond at all to the 
therapy (Loges et al., 2010). Other cancer patients, who initially respond to the therapy, experience a 
survival benefit just in the range of months, without reaching a permanent cure (Kerbel, 2008). 
Furthermore, pre-clinical studies have shown that anti-angiogenic treatment suppresses tumor growth 
but simultaneously selects more invasive cancer cell clones, with high metastatic potential (Ebos et al., 
2007; Paez-Ribes et al., 2009). However, these findings have not been confirmed by clinical data (Singh 
et al., 2012b).  
Several pre-clinical studies focused their attention on the clarification of the mechanisms behind therapy 
refractoriness and evasive escape. Current hypotheses include i) alternative pathways of tumor 
vascularization, that are independent of sprouting angiogenesis, such as vascular cooption and 
intussusception (di Tomaso et al., 2011; Kienast et al., 2010), ii) activation of other signaling pathways 
that could compensate VEGF blockade, such as Ang-Tie, EGF-EGFR and FGF-FGFR (Vasudev and Reynolds, 
2014), iii) pericyte recruitment on the endothelium, making the EC less responsive to VEGFR2 targeting 
(Erber et al., 2004) or iv) strong selective pressure on tumor cells that need to survive in an adverse and 
hypoxic tumor milieu, leading to the survival of the most resistant clones (Wong et al., 2015). Another 
reason of anti-angiogenic resistance is the v) recruitment of myeloid derived suppresser cells Cd11b+ 
Gr1+ to the tumor site (Ebos et al., 2007; Shojaei et al., 2007; Shojaei et al., 2009). Anti-angiogenic 
treatment stimulates the production of pro-inflammatory cytokines such as granulocytes stimulating 
factor (GCSF) and SDF1, which induce the recruitment of the resistance mediating Cd11b+ Gr1+ cells. 
These cells produce Bv8 (Bombina variagata peptide 8), that stimulates tumor angiogenesis, rendering 
tumors resistant to anti-angiogenic treatments. In conclusion, the combination of anti-angiogenic 
therapy with drugs interfering with the mechanisms inducing resistance, could improve anti-angiogenic 
drug efficacy.  
1.7 Ang/Tie system 
The Angiopoietin (Ang)-Tie system, together with the VEGF/VEGFR signaling, represent the two 
pathways that are almost exclusively specific for EC. The Ang-Tie system is comprised of two receptors, 
Tie1 and Tie2 (or TEK), and four Angiopoietin ligands Ang1, Ang2, Ang4 and its mouse orthologue Ang3 
(Dumont et al., 1992; Korhonen et al., 1992; Maisonpierre et al., 1993; Partanen et al., 1992; Sato et al., 
1993), which together form the angiopoietin growth factor family. The angiopoietins and their 
endothelial Tie receptors are essential for blood and lymphatic vessel development, for the regulation of 
sprouting angiogenesis, vascular remodeling and endothelial maturation, and they play an important 
role in vascular permeability, inflammation and tumor vascularization (Augustin et al., 2009).  
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1.7.1 The structure of Tie receptors and angiopoietin ligands 
Tie1 and Tie2, whose acronym stands for Tyrosine kinase with Ig and EGF homology domains (Partanen 
et al., 1992), are single transmembrane molecules with an extracellular ligand-binding domain and a split 
intracellular Tyr kinase domain. They are highly homologous receptors, sharing 76% and 33% similarities 
in their intracellular and extracellular domains, respectively (Schnurch and Risau, 1993). The extracellular 
domains are composed of two amino-terminal immunoglobulin (Ig)-like domains, three epidermal 
growth factor (EGF) homology domains, a third Ig-homology domain and finally three fibronectin type III 
domains that are adjacent to the transmembrane domain (Jones et al., 2001). The intracellular kinase 
domain can bind to different molecules after phosphorylation (Fig. 6a).  
 
 
Figure 6: Structure of Tie receptors and angiopoietin ligands 
a) Tie receptors are transmembrane receptor Tyrosine kinases, showing a similar overall domain structure. Their 
extracellular domain consists of two immunoglobulin-like (Ig) domains, followed by three EGF-like domains, a third 
Ig-like domain and three fibronectin type III domains. The transmembrane domain is followed by the intracellular 
domain, which consists of a split tyrosine kinase domain. b) The Angiopoiein ligands are secreted glycoproteins that 
comprise of an N-terminal coiled-coil domain and a C-terminal fibrinogen-like domain. Ang ligand monomers 
oligomerize via the parallel coiled-coil domain and the superclustering domain. Ang1 primarily forms tetramers, 
while Ang2 exists mostly as dimers. 
 
The four Angiopoietin ligands are secreted glycoproteins, sharing high homology in their amino acid 
sequence. They present a small amino-terminal domain that regulates ligand clustering (superclustering 
region), followed by a large coiled-coil motif, a short linker peptide and a carboxy-terminal fibrinogen-
homology domain (Fig. 6b). The coiled-coil motif is essential for angiopoietin dimerization and 
oligomerization, while the fibrinogen-homology domain at the C-terminal is important for receptor 
binding (Davis et al., 2003; Procopio et al., 1999). Electron microscopy studies have demonstrated that 
both Ang1 and Ang2 can form multimers with trimeric, tetrameric and pentameric oligomers. While 
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Ang1 primarily forms tetramer or higher order multimers (Kim et al., 2005), Ang2 exists mostly as dimers. 
The oligomerization status of these ligands influences the receptor binding and activation. In particular, 
Ang1 multimeric structures can bind both ligand-binding sites of extracellular Tie2 homodimers and 
therefore strongly activate Tie2 receptor (Leppanen et al., 2017). Due to its dimeric conformation, Ang2 
fails to bridge Tie2 extracellular domain homodimers, limiting receptors dimerization and activation 
(Leppanen et al., 2017). Therefore it acts either as antagonist of Ang1 mediated Tie2 signaling or as a 
partial agonist (Maisonpierre et al., 1997; Yuan et al., 2009).  
1.7.2 Expression of Tie receptors and angiopoietin ligands 
The endothelial-specific Tie receptors are expressed in blood and lymphatic endothelium and are 
ubiquitous expressed during mouse embryonic development (Dumont et al., 1992; Korhonen et al., 
1994). In the adult endothelium, Tie2 is uniformly expressed and constitutively activated in stalk and 
phalanx cells, whereas it is transcriptionally downregulated upon EC activation in angiogenic tip cells (del 
Toro et al., 2010; Felcht et al., 2012). In particular, it has been shown that Tie2 cell surface presentation 
in tip cells is counter-regulated by Tie1 expression (Savant et al., 2015). In contrast, Tie1 is dynamically 
expressed upon exogenous activation. Its expression is induced by VEGF, turbulent shear stress in vessel 
bifurcations, and hypoxia, hinting at a positive role of Tie1 during sprouting angiogenesis (Chen-Konak et 
al., 2003; Porat et al., 2004). In the retina vasculature, Tie1 has a mosaic expression pattern in the 
angiogenic front, whereas it is negatively transcriptionally regulated under conditions of laminar flow 
and, therefore, in the quiescent endothelium (Savant et al., 2015). Yet, enhanced Tie1 expression has 
been reported in the vasculature of several primary tumors (Brown et al., 2000; Hatva et al., 1996; Hatva 
et al., 1995; Kaipainen et al., 1994; Lin et al., 1999; Salven et al., 1996) and it has been found to be 
correlated with metastatic melanoma progression (Kaipainen et al., 1994). Tie receptors are also 
expressed by circulating hematopoietic cells, including megakaryocytes, hematopoietic stem cells and 
osteoblasts in the bone marrow niche (Yano et al., 1997). In particular, Tie2 is expressed by a 
subpopulation of monocytes (Tie2-expressing monocytes) that are highly angiogenic in tumors (De Palma 
et al., 2005; De Palma et al., 2003). 
Angiopoietin ligands have a distinct expression pattern. Ang1 is expressed by perivascular cells like SMC, 
pericytes and fibroblasts, but it can be expressed also by tumor cells (Stratmann et al., 1998; Sugimachi 
et al., 2003). In healthy adults, Ang1 is constitutively produced and released by peri-endothelial cells and 
activates Tie2 receptor in a paracrine manner. Ang1, but not Ang2, can bind the extracellular matrix 
(ECM) via its linker peptide motif (Xu and Yu, 2001). Ang2, on the contrary, is almost exclusively 
produced by endothelial cells. It is normally stored in granules called Weibel-Palade bodies and, after 
endothelial activation, is released and binds Tie2 in an autocrine manner (Fiedler et al., 2004). Under 
physiological conditions, Ang2 expression is limited to vessel remodeling regions, but during pathological 
condition such as tumor angiogenesis and sepsis, it is strongly upregulated (Orfanos et al., 2007). 
Inflammatory cytokines, including Ang2 itself, induce a rapid release of the ligand from the Weibel-
Palade bodies, making Ang2 an important regulator of the fast endothelial response to inflammation, 
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permeability and coagulation (Fiedler and Augustin, 2006; Fiedler et al., 2006). Factors like shear stress, 
hypoxia and VEGF, transcriptionally regulate Ang2 expression (Mandriota and Pepper, 1998; Oh et al., 
1999). Importantly, laminar flow regulated transcription factor Kruppel-like factor 2 (KLF2) suppresses 
Ang2 expression, contributing to the endothelial quiescence (Parmar et al., 2006).  
1.7.3 Ang/Tie system: loss-of-function and gain-of-function studies  
The functional role of the Ang-Tie system has been further investigated through the generation of knock-
out and overexpressing mice for Angiopoietin ligands and Tie receptors. These studies have highlighted 
the importance of Tie1 and Tie2 as well as Ang1 and Ang2 during physiological angiogenesis, while 
demonstrating their dispensable role during vasculogenesis.  
Tie2 global deletion (Tie2-KO) leads to embryonic lethality and the mice die between embryonic day (E) 
10.5 and E12.5 due to impaired vascular network formation (Dumont et al., 1994; Sato et al., 1995). In 
particular, Tie2-KO mice develop normally through the early steps of primary capillary plexus formation 
but the vascular network fails to remodel and remains poorly organized with fewer endothelial cells and 
branches (Dumont et al., 1994). Further studies have shown also a direct role of Tie2 in hematopoiesis 
and heart development (Takakura et al., 1998). On the contrary, a hyperactive mutant form of Tie2, 
resulting from a missense mutation in the kinase domain of the receptor tyrosine kinase, causes venous 
malformations with dilated vessels (Vikkula et al., 1996), and its overexpression in the skin causes 
psoriasis-like phenotype characterized by epidermal hyperplasia, altered dermal angiogenesis and 
inflammation (Voskas et al., 2005). 
Mice globally deficient for Tie1 (Tie1-KO) show no significant perturbation in the first steps of embryonic 
angiogenesis but they die at later stages of embryonic development between E13.5 and birth (Puri et al., 
1995; Sato et al., 1995) due to edema and hemorrhage, caused by lack of vessel integrity. In contrast to 
Tie2-KO, Tie1-KO mice do not show any defect in hematopoiesis (Rodewald and Sato, 1996). 
Interestingly, during development Tie1 receptor is expressed on the venous lymph endothelial 
progenitor cells and lymphatic vessels. Indeed, mouse embryos with a hypomorphic Tie1 allele present 
abnormal lymphatic patterning and architecture, decreased lymphatic draining efficiency and dilated 
jugular lymph sacs. The severity of the phenotypes observed correlates with the expression levels of 
Tie1, confirming dosage dependence for Tie1 in lymphatic endothelial cells (LEC) integrity and survival 
(D'Amico et al., 2010; Qu et al., 2010). Recent studies have also shown an involvement of Tie1 in valve 
morphogenesis and collecting vessel development (Qu et al., 2015). The double deletion of Tie1 and Tie2 
resemble the phenotypes observed in Tie2-KO mice, underlying the essential role of Tie2 in the 
endocardium (Puri et al., 1999).  
Ang1 deficiency phenocopies the Tie2-KO phenotype and leads to embryonic lethality at E12.5 (Suri et 
al., 1996). This study further confirms the agonistic role of Ang1 on Tie2 receptor, underlying the pivotal 
position of Ang1/Tie2 axis in the maintenance of endothelial quiescence. Nevertheless, as discussed for 
Tie2 gain-of-function studies, overexpression of Ang1 leads to severe adverse effects. In particular, Ang1 
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hyperactivity in the skin leads to hypervascularization, with larger and highly branched vessels (Suri et 
al., 1998), as well as decreased vessel permeability (Thurston et al., 1999).  
Ang2, on the other hand, has been described as an antagonist of Ang1/Tie2 signaling as its 
overexpression results in mid-gestational lethality, similar to Ang1 and Tie2 deficiency (Maisonpierre et 
al., 1997). Ang2-KO mice do not show any apparent defects and the pups are born normal (Gale et al., 
2002), suggesting that this ligand is dispensable for normal embryonic development. Nevertheless, the 
mice show compromised vascular sprouting and remodeling in the postnatal-retina angiogenesis, with 
lack of hyaloid vessels regression after birth (Gale et al., 2002; Hackett et al., 2002). Furthermore, 
depending on the genetic background, Ang2-KO mice develop lymphatic defects, such as chylous ascites 
(Gale et al., 2002).  
In summary, Ang/Tie signaling is a multifunctional pathway that controls the quiescent EC phenotype in 
the adults but also the remodeling process that occurs during vessel formation and maturation in active 
angiogenesis. 
1.7.4 Ang1-induced Tie2 signaling 
In the quiescent endothelium, Ang1 is constitutively released by perivascular cells and binds to Tie2 
receptor, inducing its phosphorylation. The Ang1/Tie2 complex translocates to the cell-cell contacts and 
forms trans-endothelial complexes with Tie2 molecules from the neighboring cells. This leads to the 
recruitment of adaptor proteins like growth factor receptor-bound protein2 (GRB2) and p85, regulatory 
subunit of the phosphoinositide 3-kinase (PI3K). This complex activates the AKT survival-pathway that 
involves survivin, endothelial nitric oxide synthase (eNOS) while suppressing apoptotic pathways (Fig. 6a) 
(DeBusk et al., 2004; Kim et al., 2000b; Kwak et al., 1999; Papapetropoulos et al., 2000). Ang1-mediated 
Tie2 activation can also repress Ang2 expression: AKT phosphorylates and inactivates the forkhead 
transcription factor, FOXO1, which usually translocates to the nucleus and activates Ang2 expression 
(Daly et al., 2004). By contrast, when the AKT survival pathway is inhibited, FOXO1 is activated, and Ang2 
expression is induced, causing endothelial destabilization (Tsigkos et al., 2006).  
  
1. Introduction  
 
 23 
 
Figure 7: Angiopoietin-Tie signaling 
a) In resting endothelial cells, Ang1 mediated phosphorylation of Tie2 leads to the recruitment of adaptor proteins, 
such as Grb2 and the p85 subunit of PI3K, which results in the activation of AKT signaling. AKT activates survival 
promoting pathways while downregulating apoptotic genes. b) Ang1 induced Tie2 signaling is also involved in the 
inhibition of vascular permeability. In presence of Ang1, Tie2 phosphorylation mediates the activation of mDia 
(mammalian diaphanous), which sequesters Src, preventing VE-Cadherin phosphorylation and internalization, and 
therefore increased permeability.  
 
Ang1/Tie2 signaling is also directly involved in the regulation of EC permeability. In particular, Tie2 
mediates the sequestration of the non-receptor Tyr kinase Src. Src is phosphorylated during VEGF-
mediated permeability, causing the activation of Rac. Consequently, Rac phosphorylates the junctional 
protein VE-cadherin, thereby recruiting beta-arrestin-2, and leading to VE-Cadherin internalization from 
junctional complexes and promoting VEGF-dependent vascular permeability (Dejana et al., 2008; Gavard 
and Gutkind, 2006). Tie2 signaling promotes sequestration of Src by mDia (mammalian diaphanous) in a 
small GTPase, RhoA-dependent manner, leading to the anti-permeability response of the endothelium 
(Fig. 7b) (Gavard et al., 2008). Thus, in resting endothelial cells Ang1 has vascular protective effects, 
maintaining vessel integrity and limiting permeability. While in conditions of endothelial activation (in 
the absence of endothelial cell junctions), Ang1 induces endothelial cell migration and proliferation. In 
this scenario, Ang1 mediates translocation of Tie2 to cell-substratum contacts, triggering ERK1/2 
signaling, which in turns leads to FAK (focal adhesion kinase) phosphorylation (Kim et al., 2000a) and 
therefore migration. This prepares the endothelium for an angiogenic response (Fukuhara et al., 2008).  
Ang1/Tie2 pathway is also involved in the recruitment of perivascular cells (Augustin et al., 2009), which 
surround the vessel wall and are essential in promoting vascular maturation and maintaining vascular 
quiescence. Although the mechanisms are still not clear, it is well known that Ang1-mediated Tie2 
activation leads to expression of endothelial heparin-binding epidermal-like growth factor (HB-EGF), 
which causes migration of SMC (Iivanainen et al., 2003). Similarly, HGF leads to Ang1 mediated 
recruitment of SMC to the vasculature (Kobayashi et al., 2006). Furthermore, serotonin has also been 
implicated to play a role in Ang1/Tie2 mediated SMC recruitment to the endothelium (Sullivan et al., 
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2003). Platelet-derived growth factor B (PDGFB) is the best characterized cytokine expressed by 
endothelial cell and is important in pericyte recruitment during the formation of new blood vessels. 
During angiogenesis, sprouting endothelial cells secrete PDGFB (Heldin and Westermark, 1999), which 
signals through its receptor, PDGFRB, expressed by mural cells, resulting in proliferation and migration of 
perivascular cells during vascular maturation. However, no molecular evidence for a possible link 
between the Ang1/Tie2 and PDGFB/PDGFRB axis has been demonstrated so far. 
1.7.5 Ang2-mediated Tie2 signaling: agonist or antagonist? 
Unlike Ang1, which is the guardian of endothelial quiescence, Ang2 is important for sprouting 
angiogenesis, vessel destabilization, remodeling and vessel regression (Fiedler and Augustin, 2006). Ang2 
cannot rapidly induce Tie2 phosphorylation, but in the presence of pro-angiogenic stimuli, it binds to 
Tie2 and acts as an antagonist of Ang1-mediated Tie2 signaling (Maisonpierre et al., 1997). During vessel 
destabilization, Ang2 stimulation results in a complex formation amongst Tie2, FAK and av3 integrin. The 
latter, is internalized, ubiquitinylated and degraded, driving endothelial cells into apoptosis (Adams and 
Alitalo, 2007).  
Nevertheless, in stressed endothelial cells, Ang2 has been described to function as a Tie2 agonist. Its 
expression is rapidly induced by the transcription factor FOXO1 after inhibition of PI3K/ AKT pathway and 
it bolsters AKT activity so as to provide negative feedback on FOXO1-regulated transcription and 
apoptosis (Daly et al., 2006). The same group has provided evidence that Ang2 plays a protective role in 
tumor endothelial cells by activating Tie2, therefore underlying its agonistic activity also in a tumor 
setting (Daly et al., 2013). More recent reports have clarified the agonistic/antagonistic role of Ang2 in 
basal and inflammatory conditions (Kim et al., 2016; Korhonen et al., 2016). In pathogen-free conditions, 
autocrine Ang2 act as a Tie2 agonist, capable of promoting high phosphorylation of Tie2 and low FOXO1 
activation. This agonistic activity requires the presence of the orphan receptor Tie1. On the contrary, 
upon inflammation, Ang2 is released from Weibel-Palade bodies but the cleavage of Tie1 prevents Ang2 
agonistic activity, favoring its antagonistic action on Tie2, therefore leading to vessel destabilization (Kim 
et al., 2016; Korhonen et al., 2016). Thus, Ang2 mediated Tie2 signaling has a dual role in stabilizing the 
vasculature in physiological condition as well as destabilizing the endothelium and inducing remodeling 
in pathological settings. 
1.7.6 Ang2 signaling pathway independent of Tie2 
In the absence of Tie2, Ang2 can signal via integrins exerting angiogenic functions (Felcht et al., 2012). 
Although angiogenic tip cells upregulate Ang2 expression, they present low levels of Tie2 (del Toro et al., 
2010; Felcht et al., 2012) and high levels of integrins. In this Tie2-low setting, Ang2 binds to vß3, vß5 
and 5ß1 integrins and phosphorylates FAK on Tyrosin397, resulting in Rac activation. This results in 
endothelial cell migration and sprouting angiogenesis at the tip cell front (Felcht et al., 2012). 
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1.7.7 Ang/Tie system during pathology 
Molecules composing the Ang/Tie pathway not only play a role in vascular development/remodeling and 
in the adult endothelium for sustaining endothelial quiescence, but also in pathological conditions such 
as inflammation, atherosclerosis and tumor angiogenesis. In an animal model of sepsis, Ang1 has been 
shown to attenuate LPS-induced lung injuries and to improve animal survival via reducing microvascular 
leakage (Witzenbichler et al., 2005). Ang1 has also a protective role against the development of allograft 
arteriosclerosis (Nykanen et al., 2003) and protects the endothelium against radiation induced 
endothelial cells apoptosis (Cho et al., 2004). 
Similarly, the activation of Tie2 receptor mediated by the Tie2-agonistic synthetic peptide, Vasculotide, 
has been reported to improve the devastating outcome of sepsis (Kumpers et al., 2011). More efficient 
results have been obtained with the new antibody, ABTAA, which activates Tie2 while blocking Ang2. 
ABTAA protects the vasculature from septic damage and provides survival benefits in different septic 
models (Han et al., 2016). Tie2 activation can also prevent inflammation by interfering with the NFkB 
pathway (Hughes et al., 2003; Tadros et al., 2003). 
While Ang1 and Tie2 have protective roles, Ang2 is mostly a pro-inflammatory cytokine, upregulated in 
response to several stimuli. In particular, Ang2 potentiates the inflammatory effects induced by TNF by 
promoting the expression of adhesion molecules such as ICAM and VCAM. Indeed, Ang2-KO show an 
impaired inflammatory response when challenged with intraperitoneal injection of Staphylococcus 
aureus (Fiedler et al., 2006) and respond to hyperoxia induced acute-lung injuries with reduced oxidant-
induced injury, cell death, inflammation, permeability alteration and mortality (Bhandari et al., 2006). 
During sepsis, Ang2 serum levels are increased up to 20 fold (Orfanos et al., 2007). Its expression 
increases also during neovascularization in different pathologies such as arthritis, psoriasis (Augustin, 
2003), and in particular during tumor growth and metastasis. In tumor angiogenesis, Ang2 primarily 
antagonizes Tie2 receptor, causing endothelial destabilization and then, together with VEGF, drives 
tumor angiogenesis. Human patient sample studies have indicated its crucial role in angiogenesis of 
highly vascularized glioblastoma (Stratmann et al., 1998) and other preclinical and clinical studies have 
established its central role in the angiogenesis of several cancers such as gastric cancer (Etoh et al., 
2001), ovarian cancer (Zhang et al., 2003) and melanoma (Siemeister et al., 1999). Overexpression of 
Ang2 in tumor cell lines has produced divergent results. On one hand, Ang2 promotes tumor growth 
leading to a more invasive behavior (Ahmad et al., 2001; Etoh et al., 2001; Hu et al., 2003; Yoshiji et al., 
2005), while on the other hand Ang2 overexpression leads to disordered angiogenesis and inhibition of 
tumor growth (Ahmad et al., 2001; Etoh et al., 2001; Hu et al., 2003; Yu and Stamenkovic, 2001). 
Systemic overexpression of Ang2 leads to tumor regression in 24 hours (Cao et al., 2007), and its genetic 
deletion delays the tumor growth, affecting the early stages of tumor progression (Nasarre et al., 2009). 
Yet, Ang2 adenoviral administration can also have a protective role in atherosclerosis progression 
(Ahmed et al., 2009).  
Although Ang2 shows distinct effects on the tumor vasculature, it acts synergistically with VEGF, 
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enhancing VEGF-induced angiogenesis (Holash et al., 1999; Lobov et al., 2002). Furthermore, VEGF can 
induce transcriptional activation of Ang2 promoting tumor angiogenesis (Zhang et al., 2003). Anti-
angiogenic (AA) agents targeting the VEGF/VEGFR pathway fail to give generous benefits in survival of 
cancer patients mainly because they target unstable and immature blood vessels, leaving functional and 
normalized vessel behind (Gerald et al., 2013). Agents targeting Ang/Tie system affect later stages of 
remodeling and maturation. In order to target the synergistic effects of both tyrosine kinase systems and 
to affect different stages of tumor angiogenesis, a dual targeting approach has been successfully used in 
several pre-clinical studies, showing delayed tumor growth and prolonged survival in different 
glioblastoma model (Daly et al., 2013; Gerald et al., 2013; Hashizume et al., 2010; Kienast et al., 2013; 
Kloepper et al., 2016; Koh et al., 2010; Peterson et al., 2016). In addition to anti-VEGF antibodies, anti-
Ang2 has also been shown to improve the therapeutic benefit upon combination with standard 
chemotherapy in a primary tumor setting (Brown et al., 2010; Leow et al., 2012). The targeting of Ang2 in 
association with low dose metronomic chemotherapy, in a post-surgical adjuvant scenario, reduced the 
incidence of bone metastasis and the growth of lung metastasis, improving mice survival (Srivastava et 
al., 2014). Nevertheless, despite this pre-clinical success, a recent clinical study identified limited benefit 
of co-targeting Ang2 and VEGF in colorectal cancer (Reuters, 2016).  
1.8 Tie1 Receptor  
1.8.1 Tie1 signaling  
Tie1 was discovered in 1992, but no ligand has been identified yet, rendering its signaling still poorly 
understood. Endothelial cells express Tie1 as a doublet of 135 and 125 kiloDalton (kDa), representing the 
mature glycosylated cell surface receptor and intracellular non-glycosylated immature receptor, 
respectively (Partanen et al., 1992). Upon inflammatory conditions, the mature receptor can be cleaved 
into two fragments: a 100 kDa soluble fragment that contains the extracellular domain and is released 
upon shedding, and a 45 kDa fragment representing the transmembrane and intracellular domains which 
remain cell-associated. Tie1 cleavage is triggered by multiple factors, such as VEGF, tumor necrosis factor 
 (TNF), LPS (lipopolysaccharide), phorbol ester PMA (phorbol-12-myristate-13-acetate) and other 
inflammatory cytokines that activate metalloproteases and induce Tie1 shedding at the E749/S750 
peptide bond in the proximal transmembrane domain (Chen-Konak et al., 2003; Marron et al., 2007; 
Yabkowitz et al., 1999; Yabkowitz et al., 1997). The newly formed intracellular domain, can be further 
proteolitically cleaved by -secretase to give rise to an N-terminal truncated 42 kDa fragment, which is 
then degraded by proteasomal activity (Marron et al., 2007). Recent reports have shown that Tie1 
ectodomain shedding is important for controlling angiopoietin functions in vivo. In physiological 
condition, full-length Tie1 sustains Ang2 agonistic activity on Tie2, but its ectodomain shedding, which 
occurs during inflammation, leads to a reduction in Tie2 phosphorylation, downregulation of Tie2 and 
upregulation of Ang2. This prevents the basic agonistic action of Ang2 and favors Ang2 antagonistic role 
on Tie2, initiating a positive feedback loop through FOXO1-driven Ang2 expression that leads to vascular 
remodeling (Kim et al., 2016; Korhonen et al., 2016). Other studies have shown that the proteolytic 
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ectodomain process of Tie1 increases the responsiveness of Tie2 to Ang1, and therefore Tie2 activation. 
Mechanistically the extracellular domain of Tie1 limits the ability of COMP-Ang1, a soluble chimeric form 
of human Ang1, to bind Tie2 (Marron et al., 2007). Both full length Tie1 and the truncated receptor 
lacking the ectodomain exist as pre-formed heterodimers that bind physically to Tie2, suggesting that 
also Tie1 endodomain contrbutes to the Tie1-Tie2 complex (Seegar et al., 2010; Singh et al., 2012a). A 
very elegant study has recently demonstrated that Tie1-Tie2 heterodimerization is mediated by 
intermolecular -sheets formation between the membrane-proximal Fibronectin type III domain n3 of 
the two receptors (Leppanen et al., 2017). Interestingly, activation of Tie1 and Tie2 in heteromeric 
complexes depends on β1 integrin (Korhonen et al., 2016). In contrast to these reports, Seegar et al. 
have demonstrated that Tie1 and Tie2 form heterodimers via ectodomain electrostatic interactions, 
which inhibit Tie2 activation and clustering. According to their model, Ang1 binding to Tie2 promotes 
heterodimer dissociation, Tie2 clustering and signaling activation; Ang2 binding to Tie2, on the contrary, 
is not able to dissociate Tie1-Tie2 heterocomplexes, and therefore cannot induce Tie2 signaling, 
behaving as a competitive Tie2 antagonist (Seegar et al., 2010). Tie1, therefore, is considered as an 
inhibitor co-receptor for Tie2 signaling, which downregulates Ang1/Tie2 mediated AKT and MAPK 
phosphorylation in vitro (Yuan et al., 2007). In vivo studies have better clarified the context-dependent 
role of Tie1 on Tie2 signaling during post-natal retina vascularization. Functionally, Tie1 expression by 
angiogenic EC contributes to shaping the tip cell phenotype by negatively regulating Tie2 surface 
presentation. In contrast, Tie1 acts cooperatively to sustain Ang1/Tie2 signaling in remodeling stalk cells, 
while it is strongly downregulated in quiescent EC (Savant et al., 2015). 
 
 
Figure 8: Representation of the context dependent role of Tie1 in regulating Tie2 signaling 
Tie1 counter-regulates Tie2 cell surface presentation in tip cells and sustains Ang1-Tie2 signaling in stalk cells by 
forming heterocomplexes. In quiescent phalanx cells, Tie1 is downregulated. Figure modified from (Savant et al., 
2015).  
 
While Tie2 has a strong tyrosine kinase activity, Tie1 is not able to phosphorylate other proteins or to 
induce autophosphorylation per se. Interestingly, Tie1 phosphorylation can be induced by COMP-Ang1, 
in a Tie2 dependent manner (Saharinen et al., 2005; Savant et al., 2015; Yuan et al., 2007). In the 
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absence of Tie2, high concentration of COMP-Ang1, far from the physiological setting, can weakly 
phosphorylate Tie1. Native Ang1 and Ang4 can also induce Tie1 phosphorylation, but in a less efficient 
way than COMP-Ang1 (Saharinen et al., 2005; Savant et al., 2015). Chimeric Tie1 presenting the 
extracellular domain of CSF-1 (macrophage colony-stimulating factor 1 receptor) and its intracellular 
kinase domain has been shown to activate PI3K-AKT survival pathway and inhibit apoptosis (Kontos et 
al., 2002). This study suggests that Tie1 could potentially transduce signals similar to Tie2, but the 
absence of a specific ligand leaves the hypothesis that Tie1 could signal through additional mechanisms 
open. Recently, Reinardy et al. have investigated the role of a Threonine phosphorylation site (T794) 
within the juxtamembrane domain of Tie1. Mutation of T794 did not alter Tie1 or Tie2 tyrosine 
phosphorylation or downstream signaling, suggesting that this Threonine site could represent a novel 
Tie1 function independent from its RTK properties. In particular, under angiogenic stimuli, the small 
GTPase Rac1, activates PAK (p21-activated kinase), that in turn phosphorylates Tie1 on T794. Rac1-GTP 
associates with phospho-T794 and facilitates interactions with effector molecules that either stabilize 
Rac1 in its active GTP-bound form or mediate GTP hydrolysis and therefore Rac1 inactivation. Expression 
of a non-phosphorylated mutant of this site (T794A) in zebrafish significantly disrupted vascular 
development, resulting in fish with stunted and poorly branched intersomitic vessels (Reinardy et al., 
2015). 
1.8.2 Tie1 in pathological conditions 
Tie1 is not only involved in physiological angiogenesis but also exerts critical functions in pathological 
blood vessel formation, such as inflammatory disease and tumor angiogenesis. Tie1 expression is 
induced in atherosclerosis-prone regions of the vasculature characterized by disturbed blood flow, and 
its attenuation reduces murine atherosclerotic lesions in a dose-dependent manner (Woo et al., 2011). It 
exerts pro-inflammatory functions also in other inflammatory diseases, such as rheumatoid arthritis and 
arthritis (Jin et al., 2008). It has even been proposed to be involved in the pathogenesis of Ebola Virus 
infection (Rasmussen et al., 2014). Recently, its involvement in LPS-induced acute lung inflammation has 
been investigated in detail. Upon inflammatory conditions, Tie1 extracellular domain is cleaved and 
limits the agonistic role of Ang1 on Tie2 while promoting Ang2 antagonistic action on Tie2, favoring 
vascular destabilization (Kim et al., 2016; Korhonen et al., 2016). In addition, the serum level of Tie1 
ectodomain is significantly increased, further suggesting soluble Tie1 as a biomarker. 
Tie1 is strongly expressed in acute myeloid leukemia, myelodysplastic syndrome and chronic myeloid 
leukemia. High-Tie1 level is a predictor of shorter survival in early chronic myeloid leukemia (Verstovsek 
et al., 2001; Verstovsek et al., 2002). Tie1 overexpression has also been detected in several solid tumors, 
such as breast cancer (Salven et al., 1996), colorectal adenocarcinoma (Ito et al., 2004), metastatic 
melanoma (Kaipainen et al., 1994), gastric carcinoma (Lin et al., 1999), and thyroid neoplasm (Ito et al., 
2004). In breast cancer, Tie1 is not only increased in the vasculature, but it is also highly expressed in 
epithelial breast cancer cells and in ductal carcinoma in situ (Salven et al., 1996). Although Tie1 is not 
expressed in all microvessels of normal or malignant breast tissue, the number of Tie1-positive capillaries 
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is greater in malignant tissue than in normal breast tissue, strongly supporting Tie1 as a marker for 
tumor angiogenesis (Salven et al., 1996). In the colorectal adenocarcinoma, Tie1 expression is 
significantly correlated with histological grading, depth of tumor invasion, Duke’s classification and 
lymphatic invasion (Ito et al., 2004). In gastric adenocarcinoma, Tie1 expression is a prognostic marker 
since its expression is inversely correlated to patients’ survival (Lin et al., 1999). Furthermore, in thyroid 
tumorigenesis, Tie1 plays a role in the early phase of papillary carcinoma while it is dispensable for the 
progression of anaplastic carcinoma or follicular tumor (Ito et al., 2004).  
The involvement of Tie1 in tumorigenesis has made it an interesting molecule to study during tumor 
angiogenesis. Using a conditional knock-out mouse, D’Amico et al. have demonstrated that Tie1 
deficiency in tumor endothelium reduces tumor vascularization and tumor growth by decreasing 
endothelial cell survival in tumor microvasculature. This anti-angiogenic effect occurs via activation of 
the Notch pathway that inhibits sprouting angiogenesis (D'Amico et al., 2014). Thus, Tie1 as a potential 
target for anti-angiogenic therapy needs further investigation.  
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2. Aim of the thesis 
The orphan Tie1 receptor is essential for vascular remodeling during embryonic development as well as 
in the post-natal angiogenesis. It is upregulated in the vasculature of several primary tumors and a 
recent study has promoted the receptor as a therapeutic target for controlling primary tumor growth by 
limiting blood vessels development. Angiogenesis is a rate-limiting process not only for primary tumor 
growth but also for metastatic dissemination, considered as a multistage event critically dependent on 
the interaction of metastasizing neoplastic cells and tumor microenvironment.  
The aim of this thesis was to i) decipher the contribution of Tie1 to blood vessel formation in the early 
and late stage of tumorigenesis and to ii) dissect its pathological and mechanistic contribution to the 
main steps of the metastatic cascade, such as tumor cell intravasation, extravasation and colonization in 
distant organs. Finally, the last and most important is to iii) investigate new therapies targeting the Ang-
Tie system and to propose Tie1 as a tumor-specific target.  
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3. Results 
3.1 Endothelial Tie1 deletion during primary tumor growth induces 
necrosis and delays tumor growth at later stages 
To understand the mechanistic contribution of endothelial Tie1 during tumor progression, Tie1 floxed 
mice were used in the present study. Given that homozygous constitutive Tie1 deletion is embryonic 
lethal, Tie1flox/flox mice were created by the lab of the Dr. Scott Baldwin using the Cre/loxP system to 
conditionally delete the first coding exon of Tie1 (Qu et al., 2010). Next, Tie1flox/flox mice were crossed 
with the inducible Tg(Cdh5-cre/ERT2)1Rha (Cdh5CreERT2) mice (Wang et al., 2010b) to specifically delete 
Tie1 gene in the endothelial compartment after tamoxifen administration (Tie1iECKO). Tie1flox/flox mice 
were used as controls (Wildtype, WT). For all the experiments, Tie1 deletion efficiency was evaluated by 
qPCR of total tissue RNA lysates. Mice with less than 60% Tie1 deletion were excluded from the analyses. 
Two different tumor cell lines were inoculated subcutaneously into the left flank of syngeneic C57BL/6 
WT and Tie1iECKO mice: i) mouse Lewis Lung Carcinoma (LLC) cell line, derived from a tumor bearing lung 
of a C57BL/6 mouse (Bertram and Janik, 1980) and ii) mouse B16F10 melanoma cell line, developed in 
C57BL/6 mice (Fidler, 1975). In both models, Tie1 deletion was initiated two days after tumor cell 
inoculation (Fig. 9).  
 
Figure 9: Experimental protocol for tumor cell injection 
One million LLC or B16F10 were subcutaneously inoculated in the left flank of the mice. Five doses of tamoxifen 
(2mg/dose) were administrated into WT and Tie1
iECKO
 animals. Mice were sacrificed at day 14 after tumor cell 
inoculation. 
 
For tumor growth experiments, LLC tumors were allowed to grow until ~1 cm3 (day 18 post-inoculation) 
when mice were sacrificed. Tumor growth was monitored every three days using caliper measurements. 
The growth curves of WT and Tie1iECKO tumors progressed similarly until tumors had reached almost 1 
cm3 in size (Fig. 10A). Thereafter, growth curves diverged, resulting in a significant reduction of tumor 
volume and tumor weight of Tie1 endothelial deleted tumors (Fig. 10B). To study the consequences of 
Tie1 deletion on the intratumoral microenvironment prior to overt tumor growth divergence, tumors 
were harvested at day 14 and tumor cell hypoxia and necrosis were analyzed. Hypoxic regions were 
identified by nuclear HIF1 staining, a subunit of the transcriptional factor HIF1, master regulator of 
cellular response to hypoxia. Quantification of HIF1 positive area per tumor area revealed a drastic 
increase of intratumor hypoxia (Fig. 10C, D) in Tie1iECKO primary tumor. Consistently, tumor cell necrosis, 
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shown in the H&E staining as pink area, was significant higher in Tie1iECKO mice compared to the WT 
controls (Fig. 10E, F), already 14 days post-LLC inoculation. 
 
Figure 10: Tie1 loss influences later stages of tumor growth by promoting tumor hypoxia and necrosis 
A) LLC tumor growth curve in WT and Tie1
iECKO
 mice (n=5; two-way ANOVA test, **, p<0.01. Data are expressed as 
mean ± SEM). B) LLC tumor weight n=5, Student’s T-test, *, p<0.05). C) Bright-field microscope images of hypoxic 
area (stained with anti-HIF1α) from WT and Tie1
iECKO
 LLC tumors. Arrowheads indicate hypoxic areas. Scale bar: 1 
mm. D) Quantification of HIF1α
 
positive area from WT and Tie1
iECKO
 tumors (n=10 (WT) and 9 (Tie1
iECKO
); two-tailed 
Student’s t-test, ***, p<0.001). E) Bright-field microscope images of necrotic area (H&E staining, light pink, 
indicated by arrowheads) from WT and Tie1
iECKO
 LLC tumors. Scale bar: 1 mm. F) Quantification of the necrotic area 
from WT and Tie1
iECKO
 tumors (n=10 mice; two-tailed Student’s t-test, ***, p<0.001). 
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Similarly, B16F10 melanoma cells were inoculated subcutaneously and allowed to grow until ~600 mm3 
(day 14 post-inoculation). The growth rate of B16F10 tumors was very heterogeneous amongst the 
animals (data not shown) but the intratumoral necrosis was more severe than in LLC tumors (Fig. 11A, B). 
Therefore, mice had to be sacrificed before a divergence between the tumor growth curves was evident 
in the two experimental groups. 
In conclusion, endothelial Tie1 deletion induced severe hypoxia and necrosis in the tumor 
microenvironment, causing a tumor growth delay at later stages. 
 
 
Figure 11: Tie1 deficiency increases necrosis in B16F10 primary tumor  
A) Necrotic area (H&E staining, light pink, indicated by arrowheads) from WT and Tie1
iECKO
 B16F10 tumors. Scale 
bar: 1 mm. B) Quantification of the necrotic area from WT and Tie1
iECKO
 tumors (n=7 mice; two-tailed Student’s t-
test; p=0.06). 
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3.2 Loss of Tie1 during primary tumor growth inhibits angiogenesis and 
increases mural cell coverage without affecting vessel size 
The strong effects of the orphan receptor deletion on primary tumor hypoxia and necrosis suggested 
that Tie1 loss may affect the tumor microvasculature. Therefore, LLC and B16F10 tumors were harvested 
and processed 14 days post-inoculation, when the difference in intratumor hypoxia and necrosis was 
already evident between the two experimental groups. Immunofluorescence CD31 vessel staining of LLC 
primary tumors revealed a large and significant decrease in microvessel area as well as density in the 
Tie1iECKO tumors compared to the WT tumors (Fig. 12A-C).  
 
Figure 12: Tie1 endothelial deletion has an anti-angiogenic effect on LLC tumor vasculature 
A) Representative microscope images of cryo sections stained with the pan-endothelial cell marker CD31 in LLC 
primary tumor. Scale bar: 100 m. B) Quantification of vessel area and C) vessel density in LLC tumors from WT and 
Tie1
iECKO
 mice (n=9-10 (WT) and 10 (Tie1
iECKO
); Mann-Whitney test, ***, p<0.001, **, P<0.01,). 
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To further characterize tumor vasculature in a Tie1 targeted setting, colocalization studies of CD31 and 
Desmin or CD31 and αSMA (markers for pericytes and smooth muscle cells, respectively) were 
performed. Interestingly, Tie1iECKO tumor blood vessels displayed a significant increase of mural cells 
coverage (Fig. 13A-D) and presented a strong reduction in number of angiogenic sprouts per vessel (Fig. 
13B, D arrowheads and E), indicative of a less active and more quiescent vasculature. Further dissection 
of vessels into different sizes, ranging from small vessels (50-500μm2) to large vessels (>5000μm2) 
showed no difference between the two experimental groups (Fig. 13F).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Tie1 endothelial deletion normalizes primary tumor vasculature in LLC tumors 
A) Quantification of desmin-positive blood vessels in WT and Tie1
iECKO
 LLC primary tumors (n=10 (WT) and 9 
(Tie1iECKO); Mann-Whitney test, *, p<0.05). B) Confocal microscope images of blood vessels (stained with anti-
CD31) and pericytes (stained with anti-desmin) from WT and Tie1iECKO tumors. Arrowheads indicate angiogenic 
sprouts. Scale bar: 50 µm. C) Quantification of αSMA-positive blood vessels in LLC tumor vasculature (n=10; Mann-
Whitney test, *, p<0.05). D) Confocal microscope images of blood vessels (stained with anti-CD31) and SMC 
(stained with anti-αSMA) from WT and Tie1iECKO tumors. Arrowheads indicate angiogenic sprouts. Scale bar: 50 µm. 
E) Vessel sprouting quantification (n=5; Mann-Whitney test, **, p<0.01). F) Analysis of vessel size distribution 
within the vascularized area.  
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To validate these observations in a second tumor model, the same parameters were analyzed in B16F10 
tumors. Similarly, a strong impairment in blood vessel area and density (Fig. 14A-C) as well as an increase 
in pericytes and smooth muscle cell coverage were evident after Tie1 endothelial deletion (Fig. 15A-D).  
Taken together, these results indicate that tumors in Tie1iECKO mice have fewer, more covered and more 
mature blood vessels than the tumors in WT mice. This phenotype resembles vessel normalization, 
during which chaotic, tortuous, leaky and poorly covered tumor vessels remodel into an organization 
that is similar to the normal vessel architecture (Jain, 2013). 
 
Figure 14: Tie1 deletion reduces tumor angiogenesis in B16F10 model  
A) Representative images of WT and Tie1
iECKO
 tumors stained for the pan-endothelial marker CD31. Scale bar: 100 
m. B) Quantifications of vessel area and C) vessel density 14 days post-tumor cell inoculation (n=7; Mann-Whitney 
test, ***, p<0.001, **, p<0.01).  
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Figure 15: Tie1 loss increases perivascular coverage in B16F10  
A) Quantification of desmin-positive area colocalized with CD31 (n=7; Mann-Whitney test, **, p<0.001), and B) 
representative microscope images. Scale bar: 100 µm. C) Quantification of αSMA-positive area colocalized with 
CD31 (n=7; Mann-Whitney test, **, p<0.01), and D) representative microscope images. Scale bar: 100 µm.  
 
3.3 Tie1 deletion improves blood vessel perfusion and limits tumor cell 
intravasation in vivo and in vitro 
Mature and mural cell covered blood vessels also show improved functionality including vessel perfusion 
and reduced vessel leakiness. Therefore, functionality experiments were performed. First, vessel 
perfusion was assessed by intravenously injecting fluorescent lectin that localizes to the luminal side of 
perfused vessels, and the colocalization between CD31 and lectin was quantified. A significant increase 
of lectin-perfused blood vessels was observed in Tie1iECKO tumors compared to the WT tumors, 
suggesting an improvement in vessel functionality upon Tie1 deletion (Fig. 16A, B). 
Second, vessel permeability was subsequently conducted by intravenously injecting 100 nm fluorescent-
labelled beads and vessel leakiness was quantified by assessing the amounts of nano-beads extravasated 
from the vessels into the tumor tissue. No significant differences were observed between the two 
experimental groups (Fig. 16C, D).  
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Figure 16: Tie1 endothelial deletion leads to improved vessel perfusion  
A) Quantification of lectin perfused vessel area (n=5; two-tailed Student’s t-test, *, p<0.05). B) Microscope images 
of blood vessels (stained with anti-CD31) perfused with lectin from WT and Tie1
iECKO
 tumors. Scale bar: 100 µm. C) 
Quantification of extravasated beads into the tumor tissue (n=5 (WT) and 6 (Tie1
iECKO
); Mann-Whitney Test). D) 
Microscope images of blood vessels (stained with anti-CD31) and extravasated beads (red) from WT and Tie1
iECKO
 
tumors. Scale bar: 100 µm. 
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Since the extravasation of nano-beads is a passive process that does not completely resemble the 
interaction between tumor cells and the endothelium, an ex vivo experiment, aimed at counting the 
number of tumor cell colonies derived from circulating tumor cells (CTC) present into the blood, was 
performed. Fluorescently-labelled LLC (LLC-RFP) were injected subcutaneously in WT and Tie1iECKO mice 
and, the arterial blood of the tumor bearing mice was plated 14 days later into cell culture dishes (Fig. 
17A). After 2 weeks in culture, outgrowing tumor cell colonies were counted under a fluorescent 
microscope: 7 out of 11 WT cultures developed colonies, whereas only 2 out of 10 Tie1iECKO cultures did 
(Fig. 17B). This result suggested that, upon Tie1 endothelial deletion, a reduced number of tumor cells 
escape from the primary tumor site into the circulation. To confirm a direct involvement of Tie1 in tumor 
cell migration across the endothelium, an in vitro tumor cell transmigration assay was performed. HUVEC 
were initially transfected with non-coding siRNA (NC) or two different Tie1 targeting siRNAs (siTie1a and 
siTie1b) and then plated on transwell inserts. After 12 hours, fluorescently-labelled LLC were seeded on 
top of the HUVEC and were allowed to transmigrate through the endothelial monolayer for 8 hours (Fig. 
17C). The number of LLC migrated across the Tie1 deficient monolayers was significantly reduced if 
compare to the number of LLC migrated through the control monolayer (Fig. 17D).  
 
Figure 17: Tie1 loss reduces tumor cells transmigration in vivo and in vitro 
 A) Blood was drawn from WT and Tie1
iECKO
 tumor bearing mice 14 days post-LLC inoculation and the formation of 
tumor cells colonies was investigated. B) Number of blood samples that developed tumor cell colonies (n=11 (WT) 
and 10 (Tie1
iECKO
)). C) HUVEC were seeded on gelatin-coated transwell inserts and the PKH67-labeled LLC cells 
transmigrated in 8 h were counted. D) Percentage of transmigrated LLC through a layer of siTie1 HUVEC versus 
control; n= 3 independent experiments, each performed in triplicate, Mann-Whitney Test, **, p<0.01). 
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These results suggested that upon Tie1 deletion the endothelium is less prone to tumor cell migration. 
To check if this is related to an improvement of the integrity of the endothelial junctions, the level of an 
adherens junction marker, VE-Cadherin, was investigated. The expression level of VE-Cadherin (Cdh5) 
mRNA was increased in FACS sorted isolated tumor EC (Fig. 18A) as well as the amount of the protein in 
tumor sections was strongly augmented (Fig. 18B, C) in Tie1iECKO mice, suggesting strengthening of 
adherens junctions amongst EC upon Tie1 loss. 
Taken together, these data show that Tie1 deletion during primary tumor growth improves blood vessel 
functionality and decreases the number of tumor cells intravasated from the primary tumor site into the 
vasculature, and therefore limits the number of CTC in the circulation.  
 
 
Figure 18: Tie1 endothelial specific deletion potentiate adherens junctions 
A) Relative Cdh5 expression in isolated tumor EC (n=4 (WT) and 5 (Tie1
iECKO
); Mann-Whitney test, *, p<0.05). B) 
Confocal microscope images of blood vessels stained with VE-Cadherin and DAPI from WT and Tie1
iECKO
 tumors. 
Scale bar: 50 µm. C) Quantification of VE-Cadherin fluorescent mean intensity (arbitrary unit) (n=5, Student’s T-test, 
*, p<0.05). 
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3.4 Endothelial Tie1 loss induces vessel normalization prior to necrosis 
progression 
To investigate in more detail the role of Tie1 in determining the temporal relationship between 
angiogenesis, vascular abnormalizaiton and tumor growth, the vascular phenotypes were analyzed at 
earlier stages in a time-line experiment (days 9 and 12 post-LLC inoculation). On day 9, no major 
morphological changes in microvessel area and density as well as in desmin and αSMA-covered vessels 
were evident (Fig. 19A-D and Fig. 20A, B). Also, no difference in tumor cell necrosis between the two 
experimental groups was yet evident (Fig. 19E and Fig. 20D). Interestingly, there was already a minor, 
but significant improvement of microvessel perfusion in the Tie1iECKO group compared to control mice 
(Fig. 19F and Fig. 20C). Hence, Tie1 deletion does not significantly affect the vasculature during the initial 
phases of tumor growth, but influences primary tumor blood vessels, and subsequently tumor growth, 
only at later stages. Correspondingly, vessel area in tumors harvested on day 12 was significantly 
decreased (Fig. 19A, B and Fig. 20E, F), and mural cell coverage and perfusion were notably increased in 
Tie1iECKO tumors (Fig. 18C, D, F and Fig. 20E-G). Yet, no increase in tumor cell necrosis was detectable in 
Tie1iECKO tumors on day 12 (Fig. 18E Fig. 20H). These results demonstrate that, upon Tie1 deletion, tumor 
blood vessels acquire overtime a mature phenotype and improve their functionality at later stages, 
thereby preventing tumor cell escape.  
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In conclusion, the data indicate that EC Tie1 deletion has a direct effect on primary tumor vascularization 
prior to the onset of tumor necrosis. 
 
 
 
Figure 19: Endothelial Tie1 deletion influences later stages of primary tumor growth 
A) Quantification of vessel area B) vessel density C) desmin-positive and D) αSMA-positive blood vessels, 9 and 12 
days post LLC-inoculation (n=5; Mann-Whitney test, **, p<0.01; *, p<0.05). E) H&E quantification of primary tumor 
necrosis 9 and 12 days post-LLC injection (n=5; two-tailed Student’s t-test). F) Quantification of lectin perfused 
CD31 area (n=5; Student’s T-test, *, p<0.05). 
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Figure 20 Tie1iECKO induces vascular changes at later stages 
Representative microscope images of (A) Desmin-positive, (B) αSMA-positive and (C) lectin-positive
 
blood vessels 9 
days post LLC-inoculation in WT and Tie1
iECKO
 mice. (D) Representative H&E staining from 9 days LLC primary 
tumors. Images of primary tumor blood vessels positive for (E) Desmin
 
(F) αSMA and (G) lectin, 12 days post-
inoculation. (H) Representative H&E staining from 12 days LLC primary tumors. 
 
 
3. Results 
 
 44 
3.5 Endothelial Tie1 deletion during primary tumor growth inhibits 
spontaneous lung metastasis and prolongs survival 
Normalized primary tumor vasculature and reduced CTC in the circulation are normally associated with a 
decrease of tumor cell seeding at secondary sites and, therefore, with a limited number of metastases 
(Jain, 2014). In order to investigate the effects of endothelial Tie1 on the initial steps of the metastatic 
cascade, a tumor resection model was selected, in which the primary tumor was surgically removed once 
it had reached ~0.8 cm3 in size (day 14) (Pulaski and Ostrand-Rosenberg, 2001). This model closely 
mimics the clinical setting wherein patients generally survive the primary tumor burden due to surgery, 
but succumb to metastases that develop after surgery. Thus, LLC were subcutaneously inoculated in 
mice and Tie1 deletion was initiated during primary tumor growth via tamoxifen administration. Primary 
tumor was resected two weeks after tumor cells inoculation (Fig. 21A). Lungs were examined 3 weeks 
post-primary tumor removal for macro- and micro-metastases by immunohistological H&E staining (Fig. 
21B). At this time point, 10 out of 14 (71%) WT mice presented metastatic foci while surprisingly only 1 
out of 14 (7%) Tie1iECKO mice developed metastases (Fig. 21C). This result translated further into an 
improved overall survival of the Tie1iECKO mice compared to the WT controls. Indeed, 85% of the animals 
from the Tie1iECKO group were still alive 100 days post-surgery, whereas only 30% of WT mice survived 
during the same time (Fig. 21D).  
In summary, these data suggest that targeted deletion of Tie1 in the endothelial compartment inhibits 
spontaneous metastases formation in the lungs and increases overall survival.  
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Figure 21: Tie1 deletion during primary tumor growth decreases lung metastasis and prolongs survival 
A) Schematic representation of the experimental model: LLC were inoculated subcutaneously and Tie1 deletion 
was induced via tamoxifen administration. Tumors were surgically removed after 14 days. Mice were sacrificed and 
lungs were analyzed 3 weeks post-tumor resection. B) Representative H&E lung staining from WT and Tie1
iECKO
 
mice. Arrowheads indicate metastases. Scale bar: 3 mm. C) Number of mice that developed lung metastases (black) 
in WT and Tie1
iECKO
 mice after primary tumor removal (n=14). D) Kaplan-Meier survival curve of WT and Tie1
iECKO
 
mice after primary tumor removal (n=10 (WT) and 6 (Tie1
iECKO
); Gehan-Breslow-Wilcoxon Test; *, p<0.05. Mice with 
less than 50% Tie1 deletion were excluded from the analysis.  
 
3.6 Tie1 promotes tumor cell extravasation and seeding 
The prominent primary tumor and metastasis phenotypes (Fig. 12, 13, 17 and 21) position Tie1 function 
in the early steps of the metastatic cascade (primary tumor angiogenesis, tumor cell invasion and 
intravasation in the circulation). To investigate its contribution to subsequent stages of metastatic 
dissemination (tumor extravasation, cell seeding and colonization of secondary sites), a second 
metastasis model was employed. B16F10 melanoma cells were injected directly into the circulation, 
allowing the study of extravasation and seeding of the tumor cells into the lungs (Overwijk and Restifo, 
2001). Mice were pre-treated with 4 doses of tamoxifen, and after one week from the last injection, 
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1x105 B16F10 cells were injected into the tail vein (Fig. 22A). Fourteen days post-inoculation, lung 
metastatic foci were counted under a stereomicroscope and further confirmed by histology (Fig. 22C, D). 
Metastatic colonies were detectable in both experimental groups (Fig. 22B). Yet, Tie1iECKO mice showed a 
significant decrease in the number of metastatic foci (Fig. 22D), suggesting that the orphan receptor 
affected the ability of tumor cells to extravasate and seed. 
Taken together, the data support an important involvement of Tie1 in tumor cell transmigration through 
the endothelium both at primary tumor site (intravasation) and at secondary sites (extravasation).  
 
Figure 22: Tie1 deletion affects tumor cell extravasation and seeding 
A) Schematic representation of the experimental metastasis model. Mice were pre-injected with 4 doses of 
tamoxifen and after one week from the last administration, B16F10 cells were injected intravenously. Mice were 
sacrificed and lungs were analyzed 2 weeks post-tumor cell injection. B) Number of WT and Tie1
iECKO
 mice that 
developed lung metastasis (black) (n=5). C) H&E lung staining from WT and Tie1
iECKO
 mice. Arrowheads indicate 
metastases. Scale bar: 3 mm. D) Quantification of the number of melanoma metastases per mouse lung (n=5; 
Mann-Whitney test, *, p<0.05). 
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3.7 Endothelial Tie1 deletion does not affect the growth of seeded 
micrometastasis 
The previous experiments suggest that Tie1 affects several steps of the metastatic cascade, therefore the 
next investigation was aimed at investigating whether Tie1 deletion in EC affects the growth of seeded 
micrometastases. For this purpose, the same post-surgical metastasis model was used, but the 
tamoxifen administration was postponed after the primary tumor removal, when tumor cell seeding into 
the lungs had already occurred (Fig 23A). No difference was observed in terms of metastatic occurrence, 
as 6 out of 8 (75%) WT mice and 7 out of 8 (87.5%) Tie1iECKO mice developed post-surgical lung 
metastases (Fig. 23B). In addition, the lung metastatic area, quantified microscopically by H&E staining, 
was also similar in both experimental groups (Fig. 23C, D).  
 
Figure 23: Endothelial Tie1 deletion does not affect the growth of seeded micrometastases 
A) Schematic representation of the experimental model: LLC were injected subcutaneously and tumors were 
resected on day 14. Tie1 was deleted seven days after surgery, upon tamoxifen administration. Mice were 
sacrificed and lungs were analyzed 3 weeks post-tumor resection. B) Number of WT and Tie1iECKO mice that 
developed lung metastases (black) (n=8). C) H&E lung staining from WT and Tie1iECKO mice. Arrowheads indicate 
metastases. Scale bar: 3 mm. D) Quantification of the metastatic area in lungs from WT and Tie1iECKO mice (n=6 
(WT) and 7 (Tie1
iECKO
); Mann-Whitney test).  
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Since Tie1 deletion profoundly affected primary tumor vasculature, blood vessel area and density as well 
as vessel coverage were analysed also in the lung metastases, 3 weeks post-tumor removal. Consistently 
to the findings in the primary tumors, Tie1 genetic targeting had anti-angiogenic effect on metastatic 
vasculature, inducing a decrease in microvessel area as well as vessel density (Fig. 24A-C), although no 
significant difference in mural cell coverage was observed (Fig. 24D).  
In conclusion, similar to the primary tumor growth, Tie1 endothelial deficiency induces anti-angiogenic 
effects on the metastatic vasculature, but does not affect the growth of seeded micrometastases. 
 
 
Figure 24: Tie1 deletion has anti-angiogenic effect also on metastatic vasculature 
A) Representative microscope images of WT and Tie1
iECKO
 metastasis vasculature. Scale bar: 200 µm. Quantification 
of B) microvessel area, C) microvessel density and D) αSMA coverage of lung metastasis vasculature (n=6 (WT) and 
6-7 (Tie1
iECKO
); Mann-Whitney test, **, p<0.01, *, p<0.05).  
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3.8 Endothelial Tie1 deletion favors Tie2-expressing endothelium and 
promotes stabilization through Ang1 increase 
The orphan receptor Tie1 exerts its effects on angiogenesis and vascular maturation by contextually 
affecting Ang1/Tie2 signaling (Kim et al., 2016; Korhonen et al., 2016; Savant et al., 2015). We therefore 
performed cytokine array experiments on whole tumor lysates 14 days post-tumor cell inoculation (Fig. 
25A) in order to assess the expression of Ang1, Ang2 and other molecules, in tumors grown in WT and 
Tie1iECKO mice. The expression of both Ang1 and Ang2 was increased in tumors lysates from Tie1iECKO mice 
compared to WT mice (Fig. 25A, B). However, the ratio of Ang1 to Ang2 expression shifted towards Ang1 
(Fig. 25C), involved in endothelial maturation and quiescence maintenance. 
 
Figure 25: Tie1 deletion increases Ang1/Ang2 ratio 
A) Representative immunoblotting images of the proteome profiler. Mice were inoculated subcutaneously with LLC 
and after 14 days, whole tumors lysates were used for the cytokine array and quantified. B) Densitometric 
quantification of Ang1 and Ang2 in WT and Tie1
iECKO
 primary tumor (n=4; Mann-Whitney test, **, p<0.01 and *, 
p<0.05). C) Intensities resulting from the cytokine array in A) were analyzed and the ratio Ang1/Ang2 was 
quantified (n=4; Mann-Whitney test, **, p<0.01). D) Densitometric quantification of VEGF ligand in WT and Tie1
iECKO
 
tumors (n=4; Mann-Whitney test). 
 
In cooperation with VEGF, Ang2 promotes endothelial cell migration, proliferation and sprouting 
angiogenesis. In order to see if VEGF/VEGFR pathway was synergistically acting with Ang2/Tie2 signalling, 
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VEGF protein level and VEGFR-2 mRNA were analysed. Interestingly, intratumoral expression of VEGF 
was not significantly affected by EC Tie1 deletion (Fig 25A, D). Yet, there was a strong reduction of Vegfr-
2 mRNA expression in FACS-sorted isolated tumor EC from Tie1iECKO mice (Fig. 26A), showing that EC 
VEGFR-2 expression is strongly regulated by Ang/Tie signaling, as has been similarly observed by Hu and 
colleagues in the liver after partial hepatectomy (Hu, Srivastava et al. 2014). Unlike Vegfr-2, Tie2 mRNA 
levels in FACS-sorted isolated tumor EC was not altered (Fig. 26B) and, similarly, Tie2 protein level in 
whole tumor lysates (Fig. 26C, D) was not changed in Tie1iECKO mice. Yet, the microvessel density in 
Tie1iECKO tumors was strongly reduced (Fig. 12A-C) with pronounced reduction of angiogenic sprouts (Fig. 
13E). Given that Tie2 is negatively regulated during angiogenesis (del Toro et al., 2010; Felcht et al., 
2012), we therefore hypothesized that EC Tie1 may not directly regulate EC Tie2 expression, but rather 
affect the fraction of Tie2-negative angiogenic EC, as has been suggested during postnatal mouse retinal 
angiogenesis (Savant et al., 2015). Indeed, the colocalization index of Tie2 and the endothelial marker 
CD31 in tumor sections identified a significant increase in the percentage of Tie2-positive endothelial 
cells (stalk cells) (Fig. 26E, F), and therefore, a reduction of Tie2-negative endothelium (tip cells). In 
conclusion, the vascular normalization caused by Tie1 deletion in the primary tumor is a result of 
increased Ang1 in the tumor microenvironment that might act on the increased fraction of Tie2-positive 
endothelial cells. 
Together, these data indicate that Tie1 deletion promotes a more quiescent and mature Tie2-expressing 
endothelium that limits tumor cell intravasation and hence metastasis. 
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Figure 26: Tie1 deletion promotes vascular maturation 
A) Relative Vegfr-2 expression in isolated tumor EC (n=4 (WT) and 5 (Tie1
iECKO
); Mann-Whitney test, *, p<0.05). B) 
Relative Tie2 expression in isolated tumor EC (n=4 (WT) and 5 (Tie1
iECKO
)). C) Microscope images of CD31 positive 
blood vessels stained for Tie2. Scale bar: 100 µm. D) Quantification of CD31 and Tie2 colocalization (n=6; Mann-
Whitney test, *, p<0.05). E) Tie2 Western Blot analysis on whole tumor lysates from WT and Tie1
iECKO
 mice with 
antibodies against Tie2 and the loading control actin. Representative picture of two independent experiments. F) 
Western Blot quantification of Tie2 relative to actin control (n=5; Mann-Whitney test).  
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3.9 Tie1 targeting does not affect immune cell population  
The cytokine array performed on WT and Tie1iECKO tumor lysates clearly showed a notable upregulation 
of several cytokines following Tie1 targeting (Fig. 25A). A more detailed analysis revealed that the most 
significant changes affected either cytokines involved in the Th1 (T helper lymphocyte type 1) anti-cancer 
immune response and cytokines involved in Th2 (T helper lymphocyte type 2) immune-suppression 
response (Walsh and Mills, 2013). To better clarify which immune cell population was affected by Tie1 
deletion, a FACS analysis for the different immune populations within tumors grown for 14 days in WT 
and Tie1iECKO mice was performed. The LLC tumors did not yield any significant differences in the 
proportion of total CD45+ immune cells in both groups (Fig. 27A). Analyses of the lymphoid compartment 
showed no changes in the percentage of B cells (CD45+CD19+CD45R+) involved in the humoral immunity 
(Kurosaki et al., 2015), and T cells (CD45+CD3+) involved in the adaptive immune response (Walsh and 
Mills, 2013), that populate the primary tumors (Fig. 27B, C). Amongst the T cell population, similar levels 
of T helper cells (CD3+CD4+), cytotoxic T cells (CD3+ CD8+) and T helper 17 cells (CD3+CD4+RORγt+) were 
found (Fig. 27D). Similarly, no significant changes were detected in the myeloid compartment 
(CD45+CD11b+), important for the normal function of innate and adaptive immune response (Gabrilovich 
et al., 2012) (Fig. 27E). Indeed, the percentage of granulocytes (CD45+CD11b+Ly6G+), monocytes 
(CD45+CD11b+Ly6C+) and macrophages (CD45+CD11b+F4/80+) was not altered between WT and Tie1iECKO 
groups (Fig. 27E). Further immunofluorescent staining confirmed no differences in terms of F4/80-
positive macrophages between WT and Tie1iECKO tumors (Fig. 27F, G). 
Macrophages were also classified according to the M1-like phenotype (CD45+CD11b+F4/80+CD11c+MMR-) 
or M2-like phenotype (CD45+CD11b+F4/80+CD11c+MMR+) (Fig. 28A, B). M1-like macrophages have been 
described to be pro-inflammatory and to exhibit anti-tumor activity, while M2-like macrophages have 
been reported to be anti-inflammatory and pro-tumorigenic (Sica and Mantovani, 2012). There were no 
differences in M1 and M2-like macrophages between the two experimental groups.  
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Figure 27: Tie1 targeting does not affect immune phenotype 
LLC were inoculated subcutaneously and the tumors were used for immune FACS analysis 14 days post-inoculation. 
A) Quantification of total immune cell population infiltrated in the primary tumor. Values are expressed as number 
of cells per mg of tumor. Analysis of B) B cell and C) T cell populations. D) Characterizations of lymphoid and E) 
myeloid compartment (n=5 (WT) and 6 (Tie1
iECKO
); Mann-Whitney test). Percentage of F) Quantification of 
macrophages (anti-F4/80) in the tumor area (DAPI) of WT and Tie1
iECKO
 mice (n=10; Mann-Whitney Test). G) 
Representative microscope images of macrophages (stained with anti-F4/80) in WT and Tie1
iECKO
 primary tumors. 
Scale bar: 100 m. 
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Overall, the analyses of lymphoid and myeloid immune cell compartment in LLC tumors revealed no 
changes between WT and Tie1iECKO mice. These findings exclude any involvement of immune cell 
populations in the anti-metastatic phenotype that characterize Tie1iECKO mice, substantiating the unique 
role of Tie1 to the metastatic process.   
 
 
 
Figure 28: Tie1 endothelial deletion does not affect macrophage polarization 
Percentage of A) M1-like and B) M2-like macrophages within WT and Tie1
iECKO
 primary tumors (n=5 (WT) and 6 
(Tie1
iECKO
); Mann-Whitney test). 
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4. Discussion 
The genetic loss of Tie1 receptor in mice results in embryonic lethality between E13.5 and birth with 
defects in blood vessel integrity and haemorrhages as well as compromised capillary remodelling and EC 
survival, without overt cardiac defects (Puri et al., 1995). Savant, La Porta and colleagues have reported 
that EC-specific Tie1 deletion causes deficient retinal angiogenesis in postnatal mice (Savant et al., 2015), 
demonstrating a fundamental role of Tie1 also during developmental angiogenesis. Interestingly, Tie1 is 
not required under basal conditions in adult mice, and therefore its expression is downregulated in the 
adult vasculature. 
4.1 Function of Tie1 during primary tumor growth 
Although dispensable in the mature adult vasculature, the orphan receptor Tie1 has been found to be 
prominently overexpressed in several solid tumors such as breast cancer (Salven et al., 1996), colorectal 
adenocarcinoma (Ito et al., 2004), metastatic melanoma (Kaipainen et al., 1994), gastric carcinoma (Lin 
et al., 1999) and thyroid neoplasm (Ito et al., 2004). Tie1 receptor positively orchestrates tumor 
angiogenesis and its functional contribution to tumor progression has only recently begun to be 
explored. Conditional EC-specific Tie1 deletion in adult mice has been shown to result in decreased 
survival of EC in the tumor vasculature, leading to angiogenesis inhibition and reduced tumor growth 
(D'Amico et al., 2014). The present study was aimed at mechanistically dissecting the role of Tie1 during 
primary tumor growth and investigating its contribution to the process of metastasis, which is the main 
cause of cancer-related deaths.  
To investigate these aims, Tie1 was conditionally deleted in EC (Tie1iECKO mice) after tumor cell 
inoculation. Tumor growth and vasculature were analysed at different time points (day 9, 12, 14 and 18 
post-tumor cell inoculation) in order to detect at which stage Tie1 receptor influences tumor 
vasculature. Tumor growth in WT and Tie1iECKO mice did not differ until tumors had grown to almost 1 
cm3 in size. Thereafter, curves diverged leading to a significant inhibition of tumor growth and reduction 
of tumor weight upon Tie1 loss. This has also been reported by D’Amico and colleagues (D'Amico et al., 
2014). These results suggest that Tie1 is not required for the vascularization of the primary tumor during 
early phases of tumor growth, but rather crucial for later stages. Indeed, until day 9 post-inoculation, 
Tie1 deletion induced only subtle changes in the Tie1iECKO tumor vasculature. In contrast, a significant 
anti-angiogenic effect was observed 12 days after tumor cell injection that became even more 
pronounced on day 14. The progressive and drastic decrease in microvessel area and density in Tie1iECKO 
tumors led to a notable increase in primary tumor hypoxia and subsequently to an increment in tumor 
necrosis. The anti-angiogenic effect induced by Tie1 deletion resulted from the abrogation of the 
immature tip cell vasculature and the regression of non-functional blood vessels. These findings 
correlate with those observed during physiological post-natal retina angiogenesis in Tie1iECKO mice. 
Particularly, Tie1 deletion in the developing retina induced reduction of tip cell sprouts, promoted 
endothelial cell apoptosis and subsequently regression of the immature vasculature without any 
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influence on the mature, well perfused vessels (Savant et al., 2015). Consistently, Tie1 deletion has been 
shown to upregulate the Notch pathway: Tie1 endothelial loss induced upregulation of Notch ligands, 
Dll4 and Hey1, mainly expressed in the angiogenic tip cells, and activator of Notch signaling in the 
neighboring stalk cells in order to suppress their migration and sprouting (D'Amico et al., 2014). 
Similar to Tie1, Ang2 has been found to be upregulated in tumor blood vessels (Helfrich et al., 2009; 
Kuboki et al., 2008; Park et al., 2007; Scholz et al., 2007; Zhou et al., 2007). Its expression is closely 
associated with tumor growth, progression and metastasis (Holopainen et al., 2012; Imanishi et al., 2007; 
Nasarre et al., 2009), and has therefore been pursued as anti-angiogenic (AA) target. In particular, 
growth curve of tumors grown in Ang2-KO mice dissociated from the WT curve during early stages of 
tumor development, whereas tumor growth rates during later stages of primary tumor progression were 
similar (Nasarre et al., 2009). Furthermore, Ang2 overexpression promoted lymph node and lung 
metastasis in tumor xenograft (Holopainen et al., 2012). Although Ang2 global deletion and Tie1 
endothelial deletion have the same vessel stabilization effect on primary tumor vasculature with higher 
rates of perivascular coverage (Nasarre et al., 2009), the underlying cellular mechanisms appear to be 
different: Whereas Ang2 deletion affects mural cell coverage with a limited effect on sprouting 
angiogenesis (Nasarre et al., 2009), the increase in vessel normalization in Tie1iECKO mice results from the 
abrogation of the immature tip cell vasculature leaving behind a more covered and better perfused 
mature endothelium (this study). As such, differences in the target cell population of Ang2 and Tie1 
could mechanistically explain the success of the combinatorial treatment of Tie1 genetic deletion and 
anti-Ang2 blocking antibody in sprouting-retina angiogenesis and tumor growth inhibition (D'Amico et 
al., 2014); Oppositely,  the targeting of tip cell population promoted by both anti-VEGF antibody and Tie1 
genetic deletion makes their mechanism of action redundant and explains the inefficacy of the 
combinatorial treatment during tumor growth (D'Amico et al., 2014).  Ang2 inhibition in association with 
VEGF therapy has been shown to have pronounced effects on overall survival in preclinical tumor models 
(Kloepper et al., 2016; Peterson et al., 2016). Yet, these preclinical findings did not, so far, translate in an 
improved therapeutic effect of VEGF/Ang2 co-targeting in human clinical trials (Reuters, 2016). The 
findings of the present study provide experimental evidence suggesting that Tie1 targeting is 
mechanistically and temporally different from Ang2 blockade and support a strong rationale to exploit 
Tie1 as a therapeutic target. 
Tumor vessels are characteristically chaotic, tortuous and poorly covered by perivascular cells with loose 
junctions and excess sprouting. These features make the blood vessels leaky and inefficient for the 
delivery of oxygen and nutrients to the tumor microenvironment (Jain, 2014). During the early phases of 
tumor growth, Tie1iECKO blood vessels were phenotypically similar to the WT tumor vessels; progressively 
they acquired more mature characteristics similar to physiological vasculature, with higher perivascular 
coverage, reduced vessel sprouts, decreased vascular leakiness and improved vessel perfusion. This 
phenotype resembles vessel normalization, whereby disorganized and abnormal tumor blood vessels 
remodel into an organization similar to the physiological vessel architecture (Jain, 2013). Normalized 
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vasculature is more efficient in oxygen and nutrient delivery than abnormal tumor vasculature, and 
consists of a tighter endothelial barrier, which cannot be easily crossed by tumor cells. As tumors 
become less prone to tumor cells escape, vessel normalization is generally associated with decreased 
metastases (Jain, 2005).  Despite the vascular normalization effect, LLC and B16F10 primary tumors 
showed a notably high hypoxic and necrotic area after Tie1 targeting. This apparent discrepancy 
between normalization and hypoxia/necrosis fits well to the concept of dose-dependent normalization 
window that occurs under AA therapy (Jain, 2005; Jain, 2014). An optimal AA strategy passively prunes 
away immature, dysfunctional vessels and actively fortifies those remaining. Importantly, this short-lived 
window improves oxygenation of the primary tumor microenvironment. Higher drug doses inhibit 
angiogenesis more potently but induce also an excessive pruning of the vasculature, leading to 
decreased oxygenation and increased necrosis. In Tie1iECKO tumors, the strong anti-angiogenic effect 
similarly relates to an extremely high deletion levels of Tie1, causing hypoxia and necrosis in the tumor 
microenvironment. An ideal dose-effect balance of Tie1 targeting could avoid the side effects related to 
an excessive AA therapy and could help to achieve the highest benefits of normalization therapy. 
4.2 Function of Tie1 during tumor progression and metastasis 
The strong normalization effect induced by Tie1 endothelial deletion on the primary tumor vasculature 
led to the investigation of its contribution to metastatic progression. To understand at which step of 
metastasis Tie1 plays an important role, single steps of the metastatic cascade were analyzed (tumor cell 
intravasation, survival in the circulation, seeding, extravasation to secondary site and colonization). Thus, 
in vitro assays, different metastasis models and temporal variation of the tamoxifen administration in 
these experimental protocols were adopted.  
Surgery is often the first line of treatment adopted against primary tumors in the clinic. Nevertheless, 
patients succumb to metastatic disease that develops after operation. Similar to the clinical setting, 
surgical removal of the primary tumor in a mouse model enables the study of metastatic disease with 
spontaneous metastatic lesions establishment. The specific endothelial targeting of Tie1 during primary 
tumor growth led to the inhibition of post-surgical lung metastasis in 90% of Tie1iECKO mice and resulted 
in a successful improvement of the overall survival in Tie1iECKO mice compared to WT. Specific 
administration of tamoxifen during primary tumor growth allows the manipulation of tumor 
angiogenesis and of tumor cells intravasation into the blood stream. This last process results from the bi-
directional communication between tumor cells and the tumor-associated vasculature. To isolate and 
better examine the process of tumor cell escape into the circulation, an in vitro transwell migration assay 
was applied, mimicking the vascular crosstalk between tumor cells and EC. These in vitro reconstruction 
experiments corroborated the vessel normalization phenotype and demonstrated that Tie1-deficient 
endothelium was less prone to tumor cells transmigration. In line with this, ex vivo permeability 
experiments showed that the number of tumor cells transmigrated from the primary tumor into the 
circulation and capable of forming tumor cell colonies, were reduced upon Tie1 loss. Although Tie1 and 
Tie2 are homologous receptor tyrosine kinases, they do play opposite roles in certain conditions. In 
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contrast to Tie1 deficiency, loss-of-function in vitro experiments have shown that Tie2 silencing in the EC 
weakens endothelial adherens junctions, rendering the endothelium monolayer more permissive to 
tumor cells transmigration (Hakanpaa et al., 2015). Correspondingly, gain of function in vivo experiments 
have demonstrated that the simultaneous activation of Tie2 and blockade of Ang2 ligand by the ABTAA 
antibody, increased VE-Cadherin distribution on tumor blood vessels and limited spontaneous lung 
metastases (Park et al., 2017). Similarly, in this study, the in vivo knock-out of Tie1 in growing tumor 
blood vessels promoted strengthening of endothelial adherens junctions via increased VE-Cadherin 
mRNA and protein, and inhibited post-surgical lung metastases. Hence, Tie1 deficiency resembles Tie2 
endothelial activation phenotypes, with a robust vascular barrier and preserved vessel integrity, that 
limits the formation of spontaneous metastases.  
Once in the circulation, tumor cells can travel within the blood stream to distant sites, attach to capillary 
vessel walls and extravasate into other tissues. In order to survive the new microenvironment of distant 
organs, tumor cells either become dormant or proliferate forming metastatic lesions (Ghajar et al., 2013; 
Karrison et al., 1999). All these processes can be reassumed in a rate-limiting step, known as “seeding 
and colonization of tumor cells”. To bypass the early steps of metastatic cascade and to relate Tie1 to the 
later steps of metastasis, an experimental model was performed by directly injecting B16F10 melanoma 
cells in the circulation of Tie1iECKO and WT mice. Also in this set up, endothelial Tie1 deleted mice showed 
a reduction in the number of metastatic melanoma foci per lung, indicating an important yet potential 
role of Tie1 in driving extravasation, seeding and colonization of tumor cells during metastatic spread. 
Similar to Tie1, Ang2 ligand also interferes with the later steps of metastatic dissemination: In the same 
in vivo experimental model, Ang2 overexpression disrupted endothelial integrity and promoted lung 
metastases, while its blockade improved endothelial cell-cell junctions and limited distant metastases 
(Holopainen et al., 2012; Park et al., 2017). These results suggest that Tie1 and Ang2 drive similar effects 
not only in the primary tumor vasculature but also at distant sites, during metastatic spread and 
metastasis formation. Further studies are needed to clarify if the two molecules have a similar 
mechanism-of-action, or if they act differently, as observed in normalization of the primary tumor 
vasculature in this study.  
As mentioned previously, cancer-related deaths are generally not caused by the primary tumor, rather 
by the occurrence of mortal metastasis (Steeg, 2016). Indeed, while primary tumor growth is controlled 
to a great extent with a combination of surgery, chemotherapeutic and AA drugs, metastatic spread still 
poses an imminent clinical challenge with limited treatment options (Brezden-Masley and Polenz, 2014). 
Adjuvant AA therapy is still in its infancy and has so far not shown beneficial effects. For example, the 
BEATRICE trial showed that adjuvant bevacizumab failed to improve disease free survival in triple 
negative breast cancer patients after 3 years (Cameron et al., 2013). Similar disappointing results were 
obtained from the use of adjuvant Vanucizumab, that combine the effect of bevacizumab and anti-Ang2 
blockade in metastatic colorectal cancer (Reuters, 2016). Limited clinical success of AA drugs calls for 
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better understanding of their mode-of-action and for identifying additional new inhibitors that are able 
to overcome the current limitations of AA therapy.  
Recently, it has been shown that Ang2 targeting in a post-surgical adjuvant setting reduced the incidence 
of post-surgical bone metastasis as well as the growth of lung metastasis in mice (Srivastava et al., 2014). 
This study also demonstrated that combination of Ang2 blockade in association with low dose 
metronomic chemotherapy had additive effects on the metastatic inhibition and improved overall 
survival of mice (Srivastava et al., 2014). The present work adopted the post-surgical metastasis model to 
explore possible benefits of Tie1 targeting in a post-surgical adjuvant setting, when the seeding of tumor 
cells has already occurred and metastases have started to grow. Consequently, tamoxifen administration 
protocol was shifted after the primary tumor removal. Tie1 deletion in this adjuvant setting did not show 
any efficacy in terms of metastatic incidence and burden. Indeed, the same number of WT and Tie1iECKO 
mice developed spontaneous lung metastasis. Interestingly, as in the primary tumor, Tie1 deletion 
affected the metastatic vasculature, inducing reduction of both microvessel area and microvessel 
density. Despite the anti-angiogenic effect on the metastatic vasculature, a difference in lung metastatic 
area was not evident, as instead observed during the late phases of primary tumor growth. This 
divergence between primary tumor and metastasis might be due to the fact that the death or sacrifice of 
the mice, caused by multiple and diffuse lung metastases, occurred before a potential difference in 
metastatic burden was evident between the two experimental groups. In conclusion, unlike Ang2 
targeting, Tie1 deletion does not affect the growth of established metastatic foci in the lungs. Future 
experiments will show whether Tie1 inhibition in combination with high dose or metronomic 
chemotherapy lead to a beneficial effect as has been observed with anti-Ang2 therapy. 
4.3 Tie1 targeting favors Tie2-expressing endothelium and promotes 
stabilization through Ang1 increase 
The primary tumor milieu is characterized by dynamic networks involving cytokines, chemokines and 
growth factors that regulate the growth and maintenance of blood vessels (Jain, 2013). Tie1 endothelial 
deletion induced profound changes in the cytokine profiles within the microenvironment of Tie1iECKO 
tumors, including the expression of growth factors Ang1, Ang2 and to a smaller extent VEGF. It has 
already been reported that LLC tumors are refractory to VEGF (Shojaei et al., 2009); Yet, in Tie1iECKO 
primary tumors, a strong decrease in Vegfr-2 mRNA levels was observed in FACS isolated tumor EC. 
These results are in accordance with a recent study demonstrating that EC VEGFR-2 expression is 
strongly regulated by Ang/Tie signaling in liver regeneration (Hu et al., 2014) and also suggest that the 
tumor endothelium is less responsive to VEGF/VEGFR-2 axis compared to the Ang/Tie axis.  
Interestingly, in the primary tumor, Tie1 deletion led to an increase of Ang1 protein, therefore shifting 
the Ang1/Ang2 ratio towards Ang1. Ang1 is known to increase Tie2 activation and to maintain a 
quiescent EC phenotype while sustaining vessel integrity (Thurston et al., 2000; Thurston et al., 1999). 
Yet, it has been recently reported that sepsis-induced acute inflammation causes Tie1 ectodomain 
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shedding, which in turn leads to the downregulation of Tie2 mRNA, reduction of Tie2 phosphorylation 
and upregulation of Ang2 expression. In this context, Tie1 shedding prevents the agonistic action of Ang2 
and favors its antagonistic role on Tie2, therefore leading to vascular remodeling (Kim et al., 2016; 
Korhonen et al., 2016). Similar effects were observed in the endothelial conditional Tie1 knock-out 
mouse, where the deletion of the orphan receptor in the endothelial compartment was favoring Ang2 
antagonistic activity on Tie2 (Korhonen et al., 2016). In the current thesis, Tie1 deletion did not induce 
changes in Tie2 mRNA but promoted an increase in Tie2 protein in the tumor endothelial cells as well as 
favored Ang1 production in the tumor microenvironment, indicating an increased activation of 
Ang1/Tie2 signaling upon Tie1 endothelial deletion in tumors. In other words, Tie1 does not directly 
regulate EC Tie2 expression, but rather affects the fraction of Tie2-negative tip cells, as has been 
demonstrated during postnatal mouse retinal angiogenesis. Indeed, the colocalization of Tie2 and CD31 
in tumor blood vessels showed a higher proportion of Tie2-positive endothelium (stalk cells), and 
reduced proportion of Tie2-negative endothelium (tip cells), suggesting a less angiogenic and more 
quiescent tumor vasculature. Further studies are needed to clarify the mechanism driving Tie1 shedding 
and to decipher the context-dependent influence of Tie1 on Ang1-Ang2/Tie2 signaling. 
In summary, the current work proposes that vascular normalization caused by Tie1 deletion in the 
primary tumor is a result of both enhanced Ang1/Tie2 signaling and a vasculature that is less responsive 
to VEGF and Ang2 stimuli. 
4.4 Tie1 does not affect the immune system 
An additional important role of blood vessels is to provide gateways for the patrolling immune cells. The 
excessive production of pro-angiogenic factors creates  a local tumor microenvironment that leads to the 
preferential accumulation of immune suppressor cells in the tumor (Huang et al., 2013). The abnormal 
tumor microenvironment helps tumors evading the immune response through multiple mechanisms, 
including impairment of lymphocyte infiltration, upregulation of immune checkpoint protein expression 
via hypoxia, recruitment of regulatory T cells (Treg), and establishment of an immunosuppressive tumor 
microenvironment that impairs the function of the resident and transiting immune effector cells (Huang 
et al., 2013) (Motz et al., 2014). In contrast, tumor vessel normalization has been shown to correlate 
with immunostimulatory pathways, involved in T lymphocyte infiltration and activity (Tian et al., 2017). 
A growing body of evidence indicates that AA agents normalize the abnormal tumor vasculature and 
potentially re-educate the tumor immune microenvironment towards a more immunosupportive profile. 
Along these lines, Kloepper et al. have very recently demonstrated how Ang2/VEGF bi-specific antibody 
reprograms macrophages to anti-tumor phenotype, via promoting tumor vessel normalization (Kloepper 
et al., 2016) and Schmittnaegel et al. have shown how dual inhibition of Ang2 and VEGFA elicits anti-
tumor immunity via perivascular accumulation of IFN- expressing CD8+ cytotoxic T lymphocytes 
(Schmittnaegel et al., 2017). 
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In order to understand whether the suppression of spontaneous metastasis following Tie1 targeting was 
not only due to limited tumor cell intravasation/extravasation at secondary sites, but also due to the 
reprogramming of the immune compartment, immune cell populations infiltrated in WT and Tie1iECKO 
primary tumors were analyzed. The percentage of cells involved in either humoral response (B cells) or 
adaptive immune response (T cells) was not significantly altered upon Tie1 deletion. The amount of T 
effector cells such as CD4+ and CD8+, normally associated to vessel normalization, was unchanged. 
Similarly, the number of granulocytes, monocytes and macrophages was not different between the two 
experimental groups and the same proportion of M1-like (anti-tumorigenic) and M2-like (pro-
tumorigenic) tumor-associated macrophages was found.  
These findings indicate that Tie1 genetic deletion does not improve anti-tumor immunity. Yet, it is 
important to note that the immune profiling was performed on day 14, when the late full-grown tumor 
was well established. Further studies, conducted at earlier stages, are needed to see whether Tie1 
blockade promotes reconditioning of the tumor immune microenvironment towards an 
immunosupportive anti-tumor profile in the developing tumor. 
4.5 Model: Tie1 expressing endothelium promotes tumor angiogenesis and 
metastatic dissemination 
Taken together, the data leads me to propose Tie1 as a key-player of tumor angiogenesis, vascular 
abnormalization and, most importantly, metastatic dissemination. During pathological tumor 
angiogenesis, Tie1 is upregulated and promotes the formation of abnormal blood vessels in their feature 
and function. Tie1 expression induces vascular sprouting, counter-regulates Tie2 expression in tip cells, 
and reduces Ang1/Ang2 ratio in the tumor microenvironment promoting vessel destabilization. 
Therefore, Tie1-positive blood vessels present impaired mural cell coverage, loose endothelial cell-cell 
junctions, increased vessel leakiness and reduced vessel perfusion. The vasculature is more prone to 
tumor cell escape from the primary tumor into the vasculature and is more susceptible to tumor cell 
extravasation into secondary sites and, therefore, metastasis formation (Fig. 29).  
4. Discussion 
 
 62 
 
 
Figure 29: Tumor vasculature is abnormalized and promotes distant metastasis  
 Tumors are characterized by dense and irregular vasculature. Tumor blood vessels present weak endothelial cell-
cell junctions, impaired perivascular coverage and increased vessel leakiness, which favor metastatic dissemination. 
 
 
 
Figure 30: Tie1 targeting during primary tumor growth induces vascular normalization and blocks 
metastatic dissemination 
Tie1 deficient tumors revealed reduced vessel density, increased mural cell coverage and improved vessel 
perfusion. This physical barrier limits tumor cell intravasation and extravasation, and reduces the formation of 
spontaneous lung metastasis. 
  
4. Discussion  
 
 63 
Tie1 targeting therapy prior to primary tumor removal would limit angiogenesis and induce regression of 
non-functional blood vessels, while promoting normalization of the remaining vasculature, via the 
Ang1/Tie2 signaling axis (Fig. 30). 
4.6 Tie1 as a therapeutic target and future direction 
The therapeutic effect of Tie1 targeting during primary tumor growth has recently been reported by 
D’Amico et al (D'Amico et al., 2014). While the combination of Tie1 genetic deletion and VEGF/VEGFR 
blocking antibodies did not provide any additive inhibition of tumor angiogenesis and tumor growth, the 
combinatorial targeting of Tie1 and a soluble form of Tie2, blocking angiopoietins, resulted in improved 
tumor angiogenesis and tumor growth inhibition.  
In the present thesis, the use of sophisticated in vivo metastasis models complemented with in vitro 
experiments, enabled to investigate the role of Tie1 in individual steps of tumor progression and 
metastatic dissemination. The gained insight into Tie1 biology uncovers new AA therapeutic 
opportunities focusing on Tie1 inhibition. Normalization of the primary tumor vasculature that occurs 
upon Tie1 deletion, and the strong inhibition of post-surgical lung metastasis offers Tie1 as an appealing 
target for new AA approaches. Further studies based on the combination of Tie1 inhibition and the 
administration of chemotherapeutic agents need to be performed to show the potential of Tie1-targeted 
blood vessels and improved delivery of chemotherapeutics inside the tumor microenvironment.  
Furthermore, AA therapies have severe side effects because the pathways they target are essential not 
only for the tumor growth but also for the homeostasis of normal tissue (Carmeliet and Jain, 2011). Since 
Tie1 is predominantly expressed in activated blood vessels and it is downregulated in adult quiescent 
vasculature (Savant et al., 2015), the blockade of this receptor would have the advantage of selectively 
targeting the tumor vasculature without affecting other tissues. Finally, Tie1 blockade might provide a 
new strategy to overcome the refractoriness of tumors to the standard AA-therapy. Thus, the 
development of a Tie1 blocking antibody would be a good tool for translating pre-clinical evidence of 
Tie1 targeting into the clinics.  
 
 
 
 64 
 
5. Methods  
 
 65 
5. Methods 
5.1 Mouse experimentation  
5.1.1 Animal welfare 
Mice of the C57Bl/6 background with deletion of Tie1 gene was kindly provided by Dr. Scott Baldwin. To 
generate Tie1loxP/loxP mice, a Tie1 floxed targeting vector was constructed based on the 129-Sv mouse 
genomic fragment used by Puri et al. (Puri et al., 1995). A 940 bp HpaI-SacI fragment containing a Tie1 
minimal promoter (Iljin et al., 2002; Korhonen et al., 1995) and exon 1 (containing the initial ATG codon) 
was inserted into the floxed KpnI-ClaI sites of the pDELBOY plasmid (pDELBOY-3X), which contains an Frt-
site-flanked neomycin gene. The targeting vector was electroporated into 129 R1 embryonic stem (ES) 
cells (Nagy et al., 1993) and targeting was confirmed by Southern blotting with both 5 and 3 external 
probes and PCR with the primers 5-ATGCCTGTTCTATTTATTTTTCCAG-3 and 5-
TCGGGCGCGTTCAGAGTGGTAT-3. Correctly targeted cells were then injected into C57/BL6 blastocysts 
and two separate clones were found to transmit the targeted allele through the germline. Both lines 
were maintained on a 129-Sv and C57/BL6 background and demonstrated identical phenotypes.  
Tie1flox/flox mice were crossed with Tg(Cdh5-cre/ERT2)1Rha (Cdh5CreERT2) mice (Wang et al., 2010b) to 
specifically delete endothelial Tie1 expression. Cre recombination was induced by injecting 2 mg 
tamoxifen according the protocol indicated in each experiment. 
Tie1flox/flox mice and Tg(Cdh5-cre/ERT2)1Rha (Cdh5CreERT2) were bred in barriers. For tumor 
experiments, WT and Tie1iECKO littermate mice were transferred to a mouse room with an isolated 
ventilated cage system. All animals were monitored on a daily basis for signs of ill health and had ab 
libitum access to food and water. 
For sacrificing the mice, rapid cervical dislocation of the cervical spine was performed. A part of the tail 
was taken for re-genotyping.  
All animal experiments were performed according to the guidelines of the local Animal Use and Care 
Committees and were approved by the local regulatory committee Bezirksregierung Karlsruhe, Germany 
(G61/13 and G171/15). 
5.1.2 Tumor cell inoculation  
LLC (1x10
6
) or B16F10 (1x10
6
) tumor cells suspended in 100 μl PBS were injected subcutaneously in the 
flank region of 7-9 weeks old male-female Tie1flox/flox and Tie1flox/flox x VE-CadherinCreERT2 mice, using a 
27G needle. Tumors were grown for a period of 2 weeks. Tumor size was monitored by caliper 
measurement and tumor volume was calculated as height x length x width. To induce Tie1 deletion after 
tumor cell implantation, both control and mutant animals were intraperitoneally treated with five doses 
of 2 mg tamoxifen (Sigma) dissolved in ethanol/peanut oil. LLC and B16F10 tumors were harvested 14-18 
days after cell injection (volume from 600 mm3 to 1 cm3). Mice were sacrificed at the indicated time 
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points by cervical dislocation. Resected tumors were cleaned of skin and processed for fixation and 
staining (see 4.3 hystochemical method).  
5.1.3 Spontaneous metastasis assay 
Lewis Lung Carcinoma (LLC) model: LLC tumor cells (1x10
6
) resuspendend in 100 µl PBS were injected 
subcutaneously in the flank region of 7-9 weeks old male-female C57BL/6 Tie1flox/flox (WT) and Tie1flox/flox x 
VE-CadherinCreERT2 mice, using a 27G needle. Tumors were grown for a period of 14 days and were 
surgically resected. To induce Tie1 deletion after tumor cell implantation, both control and mutant 
animals were intraperitoneally treated with five to seven doses of 2 mg tamoxifen (Sigma) dissolved in 
ethanol/peanut oil, according to the different schedules indicated in the figures. Three weeks post-
surgery, the lungs were then harvested and processed for histological analysis. Survival studies were 
performed until natural death of the mice or until the mice needed to be sacrificed for ethical reasons. 
One hundred days post-surgery, the surviving mice were sacrificed. 
Surgical resection of tumors: Surgeries were performed under systemic anesthesia induced by 
intraperitoneal injections of a mixture of Ketamine (100 mg/kg) and Xylazine (10 mg/kg) diluted in 
isotonic 0.9% NaCl. Completely anesthetized mice were placed on a heat mat and eyes were creamed 
with bepanthen cream to avoid drying. Electrocauterization was performed to achieve hemostasis during 
the surgery. Resected tumors were cleaned of skin and processed for fixation and staining (see 4.3). 
Where indicated primary tumors were weighed. Surgical wounds of C57BL/6 mice were sutured using 
number 5 suture for the peritoneum and number 4 sutures for the skin. Mice with tumors not effectively 
removed or with subsequent tumor recurrence were removed from analyses. Mice were sacrificed at the 
indicated time points or when they showed signs of ill health. Organs were collected and processed for 
fixation and staining (see 4.2).  
5.1.3.1 Primary tumor and metastases analyses  
To quantify tumor vessel density and area, the vessel number and CD31-positive area were measured 
and normalized to the tumor area. For analysis of mural cell coverage and vessel functionality, the αSMA- 
and desmin-positive area, and the lectin-positive area, respectively, were measured, and normalized to 
the corresponding vessel area. Vessel permeability was analysed counting the number of extravasated 
beads and normalizing them to the vessel number. Analyses were performed on acquired tile scan of 
entire tumor sections. For immunohistochemistry staining, zinc-fixed lungs and primary tumors were 
paraffin-embedded, sectioned and subsequently stained with Hematoxylin and Eosin (H&E) in the 
Institute of Pathology, Heidelberg University. Sections were analyzed by a board-certified pathologist 
(C.M.) and the percentage of necrotic area/slide in each tumor was assessed. To quantify the metastatic 
burden into the lungs, H&E images were taken using Zeiss Axio Scan and subsequently analysed with Fiji 
software. The metastatic area was measured and normalized to the total lung area. One lung section per 
mouse was analyzed. In order to quantify hypoxic area, the HIF1-positive area was measured and 
normalized to the tumor area with Fiji software. 
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5.1.4 Experimental metastasis assay  
WT and Tie1flox/flox x VE-CadherinCreERT2 mice were pre-injected with four tamoxifen doses. After 7 days 
from last injection, B16F10 cells (1x105), suspended in 100 µl PBS, were injected intravenously into the 
tail vein of 7-9 weeks old mice. Lungs were collected after 2 weeks from the inoculation and the 
metastatic melanoma foci counted under a stereomicroscope. Lungs were further processed for 
histological analysis. 
5.1.5 In vivo vascular leakage  
WT and Tie1flox/flox x VE-CadherinCreERT2 tumor bearing mice were injected intravenously with 100 l of 
fluorescent beads (100 nm, LumaFluor Corp.) 4h before sacrifice. Mice were sacrificed and tumors were 
harvested, embedded in OCT and sectioned. 7 and 50 m slides were thawed, rehydrated, fixed in 
acethon/methanol and stained for anti-mouse CD31. Slides were mounted with ProLong GoldTM with 
Antifade (Invitrogen) and fluorescent images were collected on Zeiss LSM 700 confocal microscope and 
Zeiss Cell Observer. Images were analysed using ImageJ.  
5.1.6 Ex vivo culture of circulating tumor cells 
Arterial blood was isolated by cardiac puncture and kept in lithium heparin Microtainer tubes (BD 
Biosciences) on ice. 100 µL blood was plated in 10 mL DMEM plus 10% FCS, 1% Penicillin/Streptomycin in 
a 10 cm tissue culture plate and 14 days later tumor cell colonies were counted under a fluorescent 
microscope (Olympus IX71). The total number of tumor cell colonies per plate was quantified manually in 
≥2 plates for each animal on an Olympus IX71 microscope. 
5.2 Histochemical methods  
5.2.1 Preparation of zinc-fixed paraffin-embedded tissues and sections  
Following mouse dissection, lungs and tumor tissues were fixed in zinc-fixative overnight. The next day, 
samples were washed once with VE-water. Samples were further processed automatically with the spin 
tissue processor STP120 including incubations in graded ethanol series (70-85-96%), twice in 
isopropanol, twice in xylol, and stored in paraffin. Samples were manually embedded in paraffin blocks. 
7-8 μm thick tissue sections were prepared using the rotary microtome HM355S. The sectioning was 
performed from at least three different levels of the tissue sample.  
5.2.1.1 Paraffin section preparation  
Paraffin sections (7-8 μm) were dewaxed, dehydrated and rehydrated by consecutive incubations in a 
graded series of ethanol dilutions.  
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Table 1: Paraffin section preparation  
Procedure Reagent Time 
1 xylol 2 min 
2 xylol 2 min 
3 99 % ethanol 1 min 
4 80 % ethanol 10 sec 
5 70 % ethanol 10 sec 
6 VE-water 1 min 
 
Sections were rehydrated with VE-water.  
5.2.1.1.1 H&E-Staining  
Tumor sections and lungs sections were hematoxylin and eosin (H&E) stained to visualize respectively 
necrosis and metastasis. Therefore, sections were stained with filtered hemalaun for 4 min, washed with 
running tap water for up to 10 min, and then stained with 1% ethanoic eosin for 2 min. Subsequently, 
sections were washed three times with VE-water followed by dipping into graded ethanol series (70-80-
99%) and isopropanol. Before mounting with histomount, sections were treated with histoclear for 90 
sec. In addition, H&E stainings were performed at the Institute of Pathology (Heidelberg) according to 
standard protocols using Mayer ́s hemalaun (Carl Roth, Karlsruhe, Germany). Bright field images were 
obtained with Zeiss Cell Observer (20x objectives) or the Zeiss Axio Scan (10x objective) and evaluated 
manually by an experienced pathologist (Dr. Carolin Mogler, Institute of Pathology, Heidelberg) scoring 
the positively stained area.  
5.2.1.1.2 Immunohistochemistry (IHC)  
After dewaxing, dehydratation and rehydration (see above), antigen-retrieval was achieved by boiling 
the sections for 20 minutes in 0.01 M pH 6.0 citrate target retrieval buffer followed by cooling in VE- 
water for 20 min. To block background activity of endogenous peroxidases, slides were treated with 3% 
H2O2 for 15 min and washed 2x 5 min with PBS-T or TBS-T. Unspecific binding sites were blocked with 
10% rabbit serum 30 min at room temperature and further overnight slides were incubated at 4°C with 
primary antibody in the appropriate buffer (see table 18 for detailed primary antibody information). The 
next day, slides were washed 3x 5 min with TBS-T and incubated with the respective secondary antibody 
in the primary antibody buffer for 30 min at room temperature (see table 19 for detailed secondary 
antibody information). Slides were washed 3x 5 min with TBS-T. Detection was performed via a biotin-
peroxidase complex, in form of Vectastain ABC solution according to manufacturers’ protocol. To 
summarize, 1 drop of solution A was mixed into 2.5 ml PBS, followed by adding 1 drop of solution B, 
further mixing and incubation in the dark for 20 min at room temperature, added to sections for 30-40 
min at RT. Sections were rinsed with TBS-T for 3x 5 min, followed by diaminobenzidine substrate (DAB) 
treatment for 2-5 min. Sections, briefly washed with tap water, were counterstained with Hematoxylin 
for 2 min, rinsed with running tap water for 10 min, dehydrated through graded ethanol series (2x 70- 2x 
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80- 2x 96%), treated with Histoclear for 5 min and mounted with Histomount. Bright field images were 
taken at the Zeiss Axio Scan (10x objectives) and the pictures analyzed with Fiji software. 
5.2.2 Preparation of cryoblocks and sections  
Immediately after mouse dissection tumor tissues were placed in cryomold immersed in OTC Cryo- 
medium on dry ice and stored at -80 °C. 7-50 μm sections were cut using the cryo microtome Hyrax C50 
followed by drying for few minutes. Sections and frozen tumors were stored at -80 °C.  
5.2.2.1 Immunofluorescence (IF) stainings  
Cryosections were dried for 20 min at room temperature and subsequently fixed for 10 min using ice- 
cold methanol. Fixed samples were washed three times with PBS for 5 min. Samples were treated with 
blocking solution for 1 h at room temperature. Primary antibodies were applied to sections in 
appropriate dilutions in blocking serum at 4 °C overnight in the dark (see table 18 for detailed primary 
antibody information). Samples were washed three times with TBS-T. Afterwards, secondary antibodies 
were added in appropriate dilutions in TBS-T for 45 min at room temperature in the dark (see table 19 
for detailed secondary antibody information). Samples were further washed three times in TBS-T to 
remove excess secondary antibodies. Nuclei were stained with the DNA intercalating agent Hoechst 
(DAPI) in a 1:3000 dilution with the secondary antibody solution. Stained sections were mounted with 
fluoromount. Samples were stored protected from light at 4 °C until analysis.  
5.3 Image acquisition  
Fluorescent images were obtained with the Zeiss Cell Observer (10x or 40x objective) or the Zeiss Axio 
Scan microscope (10x objective). Bright field images were obtained at the Zeiss Axio Scan (10x objective) 
at the imaging core facility of the DKFZ. Fiji/Image J and Imaris softwares were used for image analysis.  
5.4 Cell culture methods 
5.4.1 Cell maintenance  
All cell types were cultured under sterile conditions in a humidified (85 %) incubator with 5 % CO2 at 
37°C. Human umbilical vein endothelial cells (HUVEC, Nov. 2015, tested by Promocell via flow cytometry 
and PCR) were cultured in Endopan3 medium with 3% fetal calf serum (FCS) and supplements according 
to the manufacturer’s protocol (PAN Biotech GmbH). HUVEC were used between passages one and six. 
Adherent cells were passaged when they reached 80-90% confluency. For passaging, the medium was 
discarded and cells washed once with PBS. Trypsin/EDTA solution (0.25% trypsin) was added and the 
cells incubated at 37 °C until they detached from the plate. Cells were spin down at 1,000 rpm for 5 min, 
medium was discarded and cells were resuspended in fresh media. Cells were re-seeded in a 1:3 ratio.  
Lewis lung carcinoma cells (LLC; obtained from ATCC, 2006) and B16F10 (obtained from ATCC, 2015) 
were cultured in DMEM supplemented with 10% FCS, 1% PS. For passaging, the medium was discarded 
and cells washed once with PBS. Trypsin/EDTA solution (0.25% trypsin) was added and the cells 
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incubated at 37 °C until they detached from the plate. Trypsin-dependent digestion was stopped with 
10% serum containing medium and cells were re-seeded in a 1:10 ratio.  
Cell lines were routinely tested for mycoplasma by PCR and tested negative.  
5.4.2 Cryopreservation and thawing of cells  
Cells were resuspended in cell-type specific medium, containing 10% DMSO and 50% FCS. Cell 
suspension was transferred into cryostatic vials (1 ml/vial). The vials were slowly frozen in an isopropanol 
containing container at -80°C overnight and then stored in a liquid nitrogen tank. For thawing, cells were 
placed in a water bath for 2 min at 37°C. Slightly thawed cells were immediately mixed with pre-heated 
medium and centrifuged at 1,000 rpm for 3 min. Pellet was resuspended in fresh media and transferred 
into tissue culture plates. The medium was replaced with fresh medium the next day.  
5.4.3 PKH staining of tumor cells  
The PKH26 Fluorescent Cell linker kit from Sigma was used for PKH labeling of tumor cells. According to 
manufacturer ́s protocol LLC cells (1 x 107) were washed with PBS and resuspended in 1 mL of Diluent C. 
4 μl of PKH26 ethanolic dye solution was added to 1 mL of Diluent C. The cell mixture was added and 
incubated for 5 min while periodic mixing. Staining was stopped by addition of equal volumes of DMEM 
containing 10% FCS and 1% PS. Following three rounds of washing with DMEM plus 10% FCS and 1% PS 
and centrifugation at 1000 rpm for 5-10 min in between, cells were resuspended in DMEM plus 2% FCS 
and 1% PS and counted before further use in the transmigration assay.  
5.4.4 Transfection with small interfering RNA (siRNA)  
HUVEC were seeded in 6-well plates at a density of 120,000 cells per well. After 24 hours pre-designed 
annealed siRNA (100 nM) was mixed with 100 μL Opti-MEM (solution A) and 5 μL Oligofectamine 
transfection agent was mixed with 100 μL Opti- MEM (solution B). Both solutions were incubated for 10 
min at RT. Solution A and B were then mixed and incubated for another 30 min and RT. HUVEC were 
washed twice with Opti-MEM and covered with 800 μL Opti- MEM after the last wash. Thereafter, the 
200 μL of siRNA-Oligofectamine transfection mix was added dropwise on the cells and incubated for 4 
hours. The transfection mix was then aspirated off and endothelial cell growth medium was added. 
Knockdown efficiency was assessed by quantitative PCR (see 4.6.4 for qPCR method). 
5.5 Cellular assays  
5.5.1 Transmigration assay  
HUVEC were transfected with siRNAs targeting Tie1 and non-targeting siRNA as control (procedure 
described above in 4.4.4). HUVEC (1 x 105) were plated in Endopan3 medium onto the top chamber of 
6.5-mm/8.0-μm 0.2% gelatin-coated Transwells (Corning) overnight. The upper and lower wells 
contained Endopan3 with 3% FCS and supplements according to the manufacturer’s protocol. Twenty-
four hours later, LLC PKH67 red fluorescent dye (Sigma) labelled (1 x 105) were added to the top chamber 
in DMEM 10% FCS, with DMEM 10% FCS in the bottom chamber. Eight hours later, Transwells were 
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washed three times in PBS, fixed with Roti-Histofix 4% for 10 min. Transwells were left at 4 °C in PBS until 
they were imaged on the fluorescent microscope Olympus IX 71 microscope (x10 magnification, 5 fields) 
per filter. Analysis was performed using Fiji/ImageJ software.  
5.6 Molecular biology methods  
5.6.1 DNA isolation and analysis from tail  
Genotyping of C57BL/6 Tie1iECKO mice was performed on genomic DNA isolated from mouse tails. Tails 
(~0.5 cm) were lysed in 200 μl Direct PCR Lysis Reagent with 10 μg Proteinase K at 55 °C overnight. To 
inactivate Proteinase K, tails were heated to 95 °C for 15 min the next day. The lysate was centrifuged for 
10 sec, and supernatant was used for subsequent PCRs. Isolated DNA was stored at -20 °C.  
5.6.1.1 PCR – Polymerase chain reaction  
PCR was performed to analyze the genotype of Tie1 wildtype and knockout mice. Tie1 genotyping 
generated a wild-type band of 150bp and a mutant band of 200bp. The following pipetting scheme was 
used for the PCR mix:  
Table 2: PCR reaction mix 
Reagent Amount 
Q-solution 4.0 µl 
10x buffer 2.0 µl 
MgCl2 1.0 µl 
dNTPs (5 mM) 0.8 µl 
Primer Tie1flox-F (10 µM) 0.3 µl 
Primer Tie1flox-R (10 µM) 0.3 µl 
Primer CdhCreErt2-F (10 µM) 1.2 µl 
Primer CdhCreErt2-R (10 µM) 1.2 µl 
Taq polymerase 0.5 µl 
Template (1 µg/µl) 2.0 µl 
H2O (nuclease-free) 6.7 µl 
Total 20 µl 
 
The PCR was performed with an Applied Biosystems thermocycler according to the PCR program 
depicted here:  
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Table 3: PCR program  
Temperature Time 
  95°C 2 min 
  95°C 30 sec 
 
60°C 1 min 
72°C 1 min 
72°C 10 min 
4°C forever 
   
The amplified DNA was analyzed directly by 1% agarose gel electrophoresis or stored at 4°C until 
analysis.  
5.6.1.2 Agarose gel electrophoresis  
1% (w/v) agarose was dissolved in 0.5x TBE buffer by heating. Ethidium bromide (5 μl/100 ml) was added 
and solution was poured into a cast tray for solidification. Samples were loaded onto the gel, which run 
at 140V for 45min. The 100 bp Generuler Plus DNA-Ladder (7 μl/well) was used as a size reference. DNA 
was visualized under UV-light and the band size was determined relative to the DNA ladder.  
5.6.2 RNA preparation from tumors  
RNA was purified from mouse tumor and lung pieces. Mouse tissue pieces were lysed with 300 μl of 
TRIzol and completely homogenized by fragmentizing with a plastic pistil. 400 μl of TRIzol were added to 
the homogenized samples. In order to separate proteins from RNA and DNA, 300 μl of chloroform was 
added and vortexed for 20 sec. After 5 min incubation at room temperature samples were centrifuged at 
10,000 rpm for 15 min at 4 °C. The aqueous phase was transferred to a new RNase- free eppendorf tube. 
RNA was precipitated after adding 1 volume isopropanol, tube inverting, and incubation for 10 min at 
room temperature. Sample was loaded onto an RNeasy spin column. RNA was prepared using the 
RNeasy Mini Kit from Qiagen according to the manifacturer’s protocol. The RNeasy spin column placed in 
a 2 ml collection tube was loaded with 700 μl of the sample, centrifuged at 10,000 rpm for 15 sec and 
flow through was discarded. The column was washed with 700 μl of RW1 wash buffer, followed by 
centrifugation at 10,000 rpm for 15 sec (flow- through was discarded). Further washing was performed 
by adding 500 μl of RPE and centrifugation at 10,000 rpm for 15 sec (flow-through was discarded). This 
step was repeated and sample was centrifuged at 10,000 rpm for 2 min (flow-through was discarded). 
The column was dried by centrifugation at full speed for 1 min. RNA was eluted from the column after 
adding 30 μl of RNase- free H2O, incubation for 1 min, and centrifugation at 10,000 rpm for 1 min. 
Concentration and purity was measured by analyzing 1 μl of sample with the RNA program of the 
Nanodrop. A 260/280 ratio of ≥2 represented protein-free RNA. Purified RNA was stored at -80°C or used 
directly for cDNA preparation.  
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RNA of FACS-sorted mouse EC was isolated with the Arcturus PicoPure RNA Isolation Kit. Cells were 
centrifuged at 500 g and 4°C for 5 min and the pellet was resuspended in 50 µl Arcturus PicoPure 
extraction buffer. RNA was isolated according to manufacturer´s instructions. RNA was eluted in 11 µl 
RNase free H2O and RNA concentrations were measured using NanoPhotometer® N60.  
RNA of cell culture cells was isolated using RNeasy Mini Kit from Qiagen according to the manifacturer’s 
protocol instructions. Cells were lysed with 200 µl lysis buffer and RNA was eluted in 30 µl RNase free 
H2O and stored at -80°C. 
5.6.3 cDNA generation  
cDNA generation was performed with the Quantitect® Reverse Transcription Kit from Qiagen according 
to manufacturer’s instructions. Template RNA was thawed on ice and 1 μg was mixed with 2 μl of gDNA 
Wipeout buffer. To reach a total volume of 14 μl, RNase-free water was added. This reaction was 
incubated for 2 min at 42°C and immediately placed on ice afterwards.  
Table 4:cDNA reaction mix 
Component Volume Final concentration 
Reverse-transcription master mix 
 
  
Quantiscript Reverse Transcriptase 1 µl   
Quantiscript RT Buffer, 5x 4 µl 1x 
RT Primer Mix 1 µl   
Template RNA 
 
  
Entire genomic DNA elimination reaction 14 µl   
Total volume 20 µl   
 
To start the transcription reaction from RNA into cDNA, the reaction was incubated for 30 min at 42°C. In 
order to achieve inactivation of the Quantiscript Reverse Transcriptase the reaction tube was then 
incubated for 3 min at 95°C. cDNA was stored at -20 °C.  
cDNA of FACS-sorted EC was amplified with QuantiTect Whole Transcriptome Kit (Qiagen) according to 
to manufacturer’s instructions and cDNA was diluted in RNAse-free water 1:250. cDNA was stored at -20 
°C. 
5.6.4 Quantitative realtime-PCR (qRT-PCR)  
Relative gene expression analysis was performed using qRT-PCR. The Taqman mono-color hydrolysis 
probe method (Applied Biosystems) was used to detect differences in the amount of mRNA transcription 
levels. This method is based on probes that are labeled with a fluorophore (6- carboxyfluorescein, FAM) 
at the 5 ́end and a fluorescence quencher at the 3 ́end. The exonuclease activity of the Taq polymerase 
cleaves the probe and thereby allows detection of the FAM fluorescence. Reactions were performed in a 
96 or 384-well plate. One reaction contained the following components:  
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Table 5: Taqman qRT-PCR reaction mix 
Reagent Volume 
Taqman FAST Universal Master Mix (ABI) 5 µl 
Taqman Probe/Primer 0.5 µl 
H2O (nuclease-free) 1.5 µl 
Total 7 µl 
+ cDNA (1:10 diluted) 3 µl 
Total 10 µl 
 
Each reaction was performed in technical triplicates. The qRT-PCR was performed using the Lightcycler® 
480 System (for the 384-well plates) or the StepOnePlus Real-Time PCR System (for the 96-well plates) 
with the following temperature profile:  
Table 6: Taqman qRT-PCR program 
TaqMan qRT-PCR program  
Step Temperature Time 
 Pre‐denaturation 95°C 30 sec 
 Denaturation 95°C 2 sec 
 
Amplification 60°C 20 sec 
 
For analysis, the ∆∆Ct method was applied as described previously (Livak and Schmittgen, 2001). This 
was done by comparing the Ct values of the samples of interest with a control. The Ct values of both the 
control sample and the samples of interest were normalized to a housekeeping gene (∆Ctgene of interest = 
Ctgene of interest-Cthousekeeping gene). Here b-actin was used as housekeeping genes. Secondly, internally 
normalized Ct values were further normalized to the mean value of all controls (WT animal, or siNS 
samples) resulting in ∆∆Ct values. Respective fold changes (FC) were calculated as the following: FC = 2
-
∆∆Ctgene of interest 
. 
5.7 Protein chemical methods  
5.7.1 Preparation of protein lysates  
Protein lysates from LLC tumors were prepared from frozen tumors. Tumor material was lysed by 
grinding with plastic pistils in 300-500 μl modified RIPA lysis buffer with phosphatase inhibitor 
orthovanadat at a concentration of 2mM (1:100). Samples were incubated on ice for 20 min. To 
sediment cellular debris, cell suspension was centrifuged for 5 min at 14,000 rpm at 4°C. The cleared 
lysate was stored at -80°C.  
5.7.2 Protein concentration measurements  
Exact protein concentrations were determined by using the BCA-assay (Pierce).  
45x 
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5.7.2.1 BCA-assay  
The BCA-assay from Pierce® with a working range from 20-200 μg/ml was performed according to 
manufacturer’s instructions for microplate formats. For the preparation of the working reagent (WR), 50 
parts of reagent A were mixed with 1 part of BCA reagent B, resulting in a mixture of 50:1. The reaction 
in the microplate was prepared as follows: 25 μl of standard or sample were mixed with 200 μl WR and 
shaken for 30 sec. The covered microplate was incubated for 30 min at 37°C. After that time, the 
microplate was measured at λ = 562 nm using a Photometer. Standard values with known concentrations 
were plotted in a graph and a standard curve was generated by linear extrapolation of the plotted 
standard values. The unknown concentration of the samples was then calculated as the following:  
x = (y-b)/a).  
5.7.3 SDS-PAGE and western blot analysis  
Proteins were separated using 8% or 10% SDS-PAGE gels depending on the protein size, and 
subsequently transferred to a nitrocellulose membrane. After blocking the membrane with 3% BSA in 
TBS-T, the respective primary antibody diluted in blocking solution was added and blots were incubated 
overnight at 4°C (see Table 18 for primary antibody information). Unbound antibody was removed by 
three washing steps with TBS-T, and the membrane was incubated with the corresponding horseradish 
peroxidase-conjugated (HRP) secondary antibody (1:5000 in TBS-T) for 45 min at RT. Following 
incubation with secondary antibody (see Table 19 for secondary antibody information), the membranes 
were washed extensively with TBS-T and incubated with enhanced chemiluminescence substrate (ECL). 
Signals were detected by exposing the membrane to a Fuji X-ray film. Actin was used as loading control.  
5.7.4 Fluorescence activated cell sorting (FACS)  
5.7.4.1 Isolation of tumor EC 
FACS sorting was performed with freshly isolated LLC tumors using a BD Biosciences FACS Aria Cell 
Sorter. Mice bearing tumors were sacrificed and tumors were minced into small pieces. Single-cell 
suspensions were prepared by digesting the tissue in Dulbecco’s Modified Eagle’s medium (DMEM) 
containing 200 U/ml Collagenase I (Sigma, C9891) and 10 μg/ml DnaseI (Sigma, D4527) at 37°C for 30 
min and subsequently sieved through a 100 μm cell strainer using the plunger of a 19 G cannula syringe. 
For isolating EC by FACS sorting, cell suspensions were stained with antibodies against CD45, Ter119, 
Lyve1 and podoplanin (Pdpn) (Table 18) to deplete blood cells and lymphatic EC for 30 min at 4°C in 
PBS/5% fetal calf serum (FCS). Cells were depleted by incubating with 500 μl magnetic Dynabeads 
(Invitrogen, 114.15D) in 750 μl PBS/5% FCS for 30 min at 4°C on the rotator. The remaining cells were 
positively stained with CD31 and CD34 antibodies (Table 18) in PBS/5% FCS for 30 min at 4°C. Dead cells 
were excluded by phosphatidylinositol (PI) staining (1:3000). CD45-Ter119-Lyve1-Pdpn-CD31+CD34+ cells 
were sorted with a BD Biosciences FACS Aria Cell Sorter.  
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5.7.4.2 Immune cell analysis 
FACS analysis was performed with freshly isolated LLC tumors using the BD Biosciences FACS Aria Cell 
Sorter. Tumors were processed as described before (4.7.4.1). For analysis of the myeloid compartment, 
cell suspensions were stained with antibody against Ly6C, Ly6G, CD45 (PacOrange), MMR, CCR2, F4/80, 
CD11c, CD11b and CD31 (APC) (Table 18) in PBS/5% FCS for 20 min at 4°C, and finally washed twice with 
PBS/5% FCS. For analysis of the T-cell compartment, cell suspensions were stained first for extracellular 
markers: anti-CD45 (PacOrange), anti-CD4, anti-CD19, anti-CD8a, anti-CD45R, anti-NK 1.1 and anti-CD3e 
in PBS/5% FCS for 20 min at 4°C. Subsequently cell suspensions were fixed and permeabilized in Cyto 
Perm/fix for 15 min at 4°C, and washed twice in 1x wash buffer. Finally, samples were stained for 
intracellular markers with antibodies against Foxp3 and RORt (Table 18). Dead cells were excluded by 
phosphatidylinositol (PI) staining (1:3000).  
5.8 Statistical analysis  
Statistical analysis was performed using GraphPad Prism (GraphPad Software). Data are expressed as 
mean ± SD or SEM (where indicated). Comparison between the two groups were made using two-tailed 
Student’s t test, Mann-Whitney test or Gehan-Breslow-Wilcoxon-Test, as indicated in the figure legends. 
Differences ≤ 0.05 were considered as statistically significant. *=P<0.05, **=P<0.01 and ***=P<0.001.   
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6. Materials  
6.1 Chemicals  
Bulk chemicals were purchased from the following companies:  
 AppliChem (www.applichem.com)   
 Carl Roth (www.carl-roth.de)   
 Gerbu (www.gerbu.de)   
 Merck (www.merk.de)   
 Roche (www.roche-apllied-science.com)   
 Serva (www.serva.de)   
 Sigma-Aldrich (www.simaaldrich.com)   
6.2 Cells 
Table 7: List of cells used in this study 
 
Cell type Company or organization 
Human umbilical vein endothelial cells (HUVEC) PromoCell 
Murine lewis lung carcinoma cell line (LLC) ATCC 
Murine lewis lung carcinoma cell line (LLC)-RFP Dr. Andreas Fischer (DKFZ) 
Murin melanoma cell line (B16F10) ATCC 
 
6.3 Cell culture and reagents  
Table 8: List of cell culture media 
Medium Cell type Company 
Endopan3 HUVEC Pan Biotech 
Dulbecco´s modified eagle medium (DMEM) Glutamax I LLC, LLC-RFP, B16F10 Gibco 
Optimem+ Glutamax HUVEC 
Life 
technology 
 
Table 9: List of reagents used in cell culture 
Reagent  Company 
Accutase, 10x  PAA Laboratories 
Dimethylsufoxide (DMSO)  Sigma-Alderich 
Dulbecco’s phosphate buffered saline (PBS) PAA Laboratories 
Fetal calf serum (FCS), heat inactivated  PAA Laboratories 
Penicillin/streptomycin (PS), 100x  PAA Laboratories 
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Reagent  Company 
Puromycin AppliChem 
Trypan blue  Gibco 
Trypsin-EDTA solution, 10x  PAA Laboratories 
 
6.4 PCR and qRT-PCR reagents  
Table 10: PCR and qRT-PCR reagents 
Component  Company 
100 bp DNA Ladder plus Fermentas 
10 x Coral Load PCR buffer  Qiagen 
Direct PCR Lysis Reagent  PeqLab 
DNase/RNase free H2O  Gibco 
dNTP mix (10mM each)  Fermentas 
Ethidium bromide Roth 
MgCl2 (25mM)  Qiagen 
6x Orange DNA Loading Dye Solution  Fermentas 
Taq DNA polymerase (5U/μl)  Qiagen 
TaqMan Fast Advanced PCR Master Mix  Applied Biosystems 
Trizol  Sigma-Aldrich 
 
6.5 Primers  
All TaqMan probes were purchased from Applied Biosystems.  
Table 11: Taqman probes for qRT-PCR 
Target gene (ms) Assay ID 
Actb (b-actin) Mm00607939_s1 
Cadherin-5 Mm03053719-s1 
Pecam Mm01242584_m1 
Tie1 Mm00441786_m1 
Tek Mm00443254_m1 
Vegfr2 Mm01222421_m1 
 
Primers for genotyping of Tie1iECKO mice were purchased from MWG Biotech and used as described in 
4.6.1.1 (www.mwg-biotech.com).  
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Table 12: Primers for genotyping of Tie1iECKO mice 
Target Sequence 
Tie1 flox/flox-F  ATGCCTGTTCTATTTATTTTTCCAG 
Tie1 flox/flox-R  TCGGGCGCGTTCAGAGTGGTAT 
Cdh5CreErt2-F  GCCTGCATTACCGGTCGATGCAACGA 
Cdh5CreErt2-R  GTGGCAGATGGCGCGGCAACACCATT 
 
6.6 Enzymes  
Table 13: Enzymes 
Enzyme Company 
Collagenase I  Sigma Aldrich 
DNase I  Roche 
Proteinase K Gerbu 
RNase free DNAse Qiagen 
 
6.7 Kits  
Table 14: Kits 
Reagent  Company 
Arcturus PicoPure RNA Isolation Kit Life Technologies 
Pierce Bicinchoninic acid (BCA) Protein Assay Kit Thermo Fischer 
Quantitect Reverse Transcription Kit for cDNA Synthesis Qiagen 
RNeasy Mini Kit Qiagen 
 
6.8 Miscellaneous 
Table 15: Miscellaneous 
 
  
Reagent Company 
Bepanthen eye cream Roche 
Betadine MundiPharma 
Ketavet  Pfizer 
Paraffin (low melting 56°C)  Merck 
Rompun  Bayer 
Tissue freezing medium (Tissue TEK)  Sakura 
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6.9 Consumables  
Table 16: Consumables 
Consumables Company 
6-well plates  Beckton Dickinson 
Cannula (18G, 19G, 27G)  BD 
Cell culture dishes (10cm, 15cm)  TPP 
Cryotubes  Carl‐Roth 
Embedding cassettes  Medim Histotechnologie 
FACS tubes  BD Falcon 
Filter containing pipette tips  Biozym 
Freezing box  Thermo Scientific 
Insulin syringe  BD 
Microscope cover glasses  VWR international 
Microscope glass slides  Menzel‐Gläser 
Pipette tips  Nerbe 
PDVF filter (0.22 µm, 0.45 µm) Millipore 
Polyamid suture (4.0) ETHICON/ETHILON 
Polyamid suture (5.0)  ETHICON/ETHILON 
qPCR plates (96-well)  Biozyme 
qPCR plates (384-well)  Roche 
Reaction tubes (0.5ml, 1.5ml, 2ml)  Eppendorf 
Reaction tubes (15ml, 50 ml)  Greiner 
Round bottom 96 well plate  Greiner 
Sealing foil  Applied Biosystems 
Sterile pipettes  Corning 
Sterile filters  Renner 
Suture clip Braun 
Syringes  Dispomed 
Tissue cultures 6-well plates  Greiner 
Tissue freezing medium (Tissue TEK)  Sakura 
Transwell permeable supports 6.5mm, 8.0µm Costar 
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6.10 Equipment  
Table 17: Equipment 
Product Company 
Agarose gel documentation system  Peqlab 
Axio Scan Zeiss 
Canto FACS Analyzer  BD 
Cell culture hood  Thermo Scientific 
Cell culture incubator  Thermo Scientific 
Cell Observer  Zeiss 
Centrifuge  Beckman Coulter 
Countess Automated Cell Counter  Invitrogen 
Cryotome  Zeiss 
Elisa reader (Multiskan)  Thermo Scientific 
Freezing box  Thermo Scientific 
Heating block  Eppendorf 
Heating mat ThemoLux 
Inverted fluorescence microscope IX71  Olympus 
Light cycler 480  Roche 
Microm HM3555  Thermo Scientific 
Multistep pipette  Eppendorf 
Nanodrop 1000 spectrophotometer  Thermo Scientific 
Neubauer Cell Counting Chamber  Marienfeld 
Pipettes  ErgoOne 
Power supply  BioRad 
Cauter set F-con 
Table centrifuge (5417R)  Eppendorf 
Thermocycler  Applied Biosystems 
UV transluminator  Intas 
Vortex  Neolab 
Water bath  Julabo 
Thermocycler  Applied Biosystems 
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6.11 Antibodies  
6.11.1 Primary antibodies 
Table 18: List of primary antibodies, their dilution and their applications 
Antigen Host Clone Conjugate Source (Cat. no.) Dilution Application 
ms αSMA mouse - Cy3 
Sigma 
(C6198 ) 
1:100 IF 
ms CCR2 rat - FITC 
R&D 
475301 
10L/16 
Cells 
FACS 
ms CD3e rat - APC-e780 
eBioscience 
17A2 
1:150 FACS 
ms CD4 rat - FITC 
Biolegend 
129.19 
1:400 FACS 
ms CD8a rat - PE-Cy5 eBioscience 53-6.7 1:400 FACS 
ms CD11b rat - PE-Cy7 
eBioscience 
M1/70 
1: 200 FACS 
ms CD11c hamster - PerCP 
Biolegend 
N418 
1:400 FACS 
ms CD19 rat - 
PerCP-
Cy5.5 
Biolegend 
6D5 
1:150 FACS 
ms CD31 rat MEC13.3 - 
BD Bioscience 
(553370/ 557355) 
1:100 IF 
ms CD31 rat - APC BD Pharmigen 1: 100 FACS 
ms CD34 rat - PCB eBioscience 1: 100 FACS 
ms CD45 rat - APC-Cy7 
BD Pharmingen 
(567659) 
1:400 FACS 
Ms CD45 rat - PE BD Pharmigen 1:200 FACS 
ms CD45 rat - PacOrange 
Invitrogen  
30-F11 
1:200 FACS 
ms Cdh5 rat - - 
BD Biosciences 
(550548) 
1:300 IF 
ms Desmin rabbit -  
Abcam 
(Ab15200-1) 
1:200 IF 
ms Foxp3 rat - V450 
eBioscience 
FJK-16s 
1:100 FACS 
ms F4/80 rat  PE 
Invitrogen 
BM8 
1:100 FACS 
ms HIF1 mouse - - 
Abcam 
ab8366 
1:100 IHC 
ms Lyve1 rat - APC-Cy7 eBioscence 1: 200 FACS 
Ms Lyve 1 rat - PE eBioscence 1: 200 FACS 
ms Ly6C rat - Apc-Cy7 
Biolegend 
HK1.4 
1:400 FACS 
ms Ly6G rat - PacBlue Biolegend 1:400 FACS 
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Antigen Host Clone Conjugate Source (Cat. no.) Dilution Application 
ms MMR rat - BV650 
Biolegend 
C068C2 
1:200 FACS 
ms NK 1.1 rat - APC 
Biolegend 
PK-136 
1:200 FACS 
Podoplanin hamster - 488 eBioscence 1: 100 FACS 
ms RORt rat - PE 
eBioscience 
B2D 
1:200 FACS 
ms Ter119 rat - APC-Cy7 BD Pharmingen 1:100 FACS 
ms Ter119 rat - PE BD Pharmingen 1:100 FACS 
ms Tie2 rabbit - - 
Santa Cruz 
(sc-324) 
1:500 WB 
ms Tie2 rat - - 
eBioscience 
14-5987-81 
1:100  IF 
 
IHC=Immunohistochemistry; WB= Western Blot; IF=Immunofluorescence; FACS=Fluorescence activated 
cell sorting; ms=mouse. 
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6.11.2 Secondary antibodies 
Table 19: List of secondary antibodies, their dilutions and applications 
Reactivity Host Conjugate Source (Cat. no.) Dilution Application 
Rat IgG goat AF488 
Life Technologies 
(A11006) 
1:500 IF 
Rat IgG goat AF546 
Life Technologies 
(A11081) 
1:500 IF 
Rabbit IgG goat AF546 
Life Technologies 
(A11071) 
1:500 IF 
Mouse IgG goat HRP 
Jackson/Dianova 
115-035-166 
1:250 IHC 
anti-rabbit goat HRP Dako Cytomation 1:1000 WB 
 
IHC=Immunohistochemistry; WB= Western Blot; IF=Immunofluorescence;  
6.12 Additional staining reagents 
Table 20: Staining Reagents 
Staining Company 
Avidin/Biotin blocking solution DAKO 
BSA  Gerbu 
Eosin Y solution  Sigma‐Aldrich 
Fluorescent mounting medium  DAKO 
Histomount Invitrogen 
Hoechst Dye 33258, 1mg/ml  Sigma‐Aldrich 
Liquid DAB Substrate Chromogen System DAKO 
Mayer’s Hematoxylin solution  Sigma‐Aldrich 
Normal goat serum  DAKO 
Normal goat serum ready‐to‐use (10%)  Zymed 
Roti‐Histofix 4% (pH 7)  Carl Roth 
 
6.13 Solutions and buffers 
Solutions and buffers for agarose-gels, FACS and Western blotting were prepared according to standard 
methods. 
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Table 21: Solutions and buffers 
Solutions Composition 
Blotting buffer (1x)  192mM  Glycine 
25mM  Trizma Base 
Digestion mix 150mg Collagenase 1A 
 0.20% DNaseI 
 50mL serum free medium 
FACS 
 
  
5% FCS in PBS 
  
Modified RIPA lysis buffer  50mM T Tris-HCl pH 7.5 
 
 
150mM  NaCl 
 1mM  EDTA 
 1% NP-40 
 0.25% Na-deoxycholate 
 100mM  Na-orthovanadate 
 1x  Protease inhibitor Mix G 
PBS-T  
 
1% [v/v]  Tween-20 in 1x PBS 
Running buffer (1x)  192mM  Glycine 
25mM  Trizma Base 
0.10% SDS 
Tris-Borate-EDTA buffer (TBE)  89mM  Tris/HCl, pH 8.0 
89mM  H3BO3 
1mM  EDTA 
Tris-Buffered Saline Tween-20 (TBS-T) 10mM  Tris/HCl, pH 7.5 
100mM  NaCl 
0.10% Tween-20 
Zinc fixative  3mM  Ca(C2H3O2)2 
2.2mM  Zn(C2H3O2)2 
3.6mM  ZnCl2 
0.1M  Tris-HCl (pH 7.4) 
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6.14 Software 
Table 22: Software 
Software Company 
Fiji  ImageJ 
FlowJo  Miltenyi Biotec 
Light Cycler 480 software  Roche 
Living Image software 4.0  PerkinElmer 
ZEN blue  Zeiss 
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7. Abbreviation 
3D 3-dimensions 
 GRB2 Growth factor receptor-bound protein2 
ACTA2 Alpha-smooth muscle actin 
ADAM a disintegrin and metalloproteases 
AF  Alexa-Fluor 
Ang Angiopoietin 
Ang2-KO Ang2 global knock out 
Angptl4 Angiopoietin like 4 
 Alpha-smooth muscle actin 
ATP Adenosine Triphosphate 
BCA  Bicinchoninic acid 
BM Basement membrane 
BRAF B-Raf-proto-oncogene Serine/Threonine Kinase 
Bv8 Bombina Variagata 8 
C Celsius 
C57BL/6J  C57 Black 6 
CCL C-C motif chemokine ligand 
CD31 Cluster of differentiation 31 
Cdh5 Cadherin 5 
cDNA  Complementary DNA 
COMP-Ang1 cartilage oligomeric matrix protein-Angiopoietin 1 
CT  Threshold Cycle 
CTC Circulating Tumor Cells 
DMSO  Dimethylsulfoxide 
DNA Desoxyribonucleic acid 
DNase  Deoxyribonuclease 
dNTP  Desoxy nucleotide triphosphate 
E Embrionic day 
EC Endothelial Cells 
ECM Extrcellular Matrix 
EGF Epidermal Growth factor 
EMT Epithelial-Mesenchymal-Transition 
eNOS endothelial Nitric Oxide Synthase 
ERK Extracellular signal regulated kinase 
FACS  Fluorescent activated cell sorting 
FAK Focal Adhesion kinase 
Fc Fusion Construct 
FCS Fetal Calf Serum 
FDA Food and Drugs Administration 
FGF Fibroblast growth factor 
FITC  Fluorescein thioisocyanate 
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FOXO-1 Forkhead Box protein O1 
FSP Fibroblast-Specific Protein 
g Gram  
h  Hour(s) 
H&E Hematoxylin/Eosin 
H2O  Water 
HB-EGF Heparin binding-epidermal growth factor 
HGF Hepatocyte growth factor 
 Hypoxia Inducible Factor 1a 
HRP  Horseradish peroxidase 
HUVEC Human Umbelical Vein Endothelial Cells 
i.p.  Intraperitoneally 
i.v. Intraveneously 
ICAM Intercellular adhesion molecule 
IGF Insulin growth factor 
IgG Immunoglobulin G 
IHC  Immunohistochemistry 
Il Interleukin 
ILK Integrin Linked Kinase 
kDa  Kilo Dalton 
KLF2 Kruppel-like-Facotor 
KO Knock Out 
l  Liter 
LEC Lymphatic Endothelial Cells 
LLC Lewis Lung Carcinoma Cells 
LOX Lysyl Oxidase 
LPS Lipopolysaccharide 
Ly6d Lymphocyte antigen 6D G6D 
Ly6g Lymphocyte antigen 6D 
M  Molar 
mAb Monoclonal antibody 
MAPK Mitogen-activated protein kinase 
MET Mesenchymal-Epithelial Transition 
min  Minute(s) 
mm  Millimeter 
MMP Matrix metalloproteinase 
ms  Mouse 
n  Nano 
NFKB Nuclear Factor kappa-light chain enhancer of activated B cells 
NK Natural Killer 
nm Nanometer 
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PAR1 Protease activated receptor 1 
PBS  Phosphate buffered saline 
PCNA Proliferating cell nuclear antigen 
PCR Polymerase chain reaction 
PDGF Platelet derived growth factor 
PDGFR Platelet derived growth factor receptor 
PFA  Paraformaldehyde 
PFS Progression Free Survival 
pH  Power of hydrogen 
PI3K Phosphatidylinositol-3-kinase  
PKC Protein kinase C  
PMA para-Methoxyanfethamine 
PTEN Phosphatase and tensin homologue 
qRT-PCR Quantitative real time polymerase chain reaction 
Rac1  Ras-related C3 botulinum toxin substrate 1 
Rho A Ras homolog gene family, member A  
RNA Ribonucleic acid 
RNase  Ribonuclease 
ROS Reactive oxygen Species 
rpm  Rounds per minute 
RT  Room temperature 
RTK Receptor Tyrosine Kinase 
RTKI  Inhibitor 
s.c.  Subcutaneous 
SD Standard Deviation 
SDS Sodium Dodecylsulfate 
SEM Standard error of the mean 
siNS Short interfering RNS Control 
siRNA Short interfering RNA 
siTie1 Short interfering target 
SMAD4 Small Mother against decapentaplegic 
SMC Smooth muscle cells 
Src Proto-oncogene tyrosine-protein kinase Src 
TAM Tumor Associated Macrophages 
TBS  Tris buffered saline 
TBS-T  Tris buffered saline with Tween 
TGF Transforming growth factor 
Tie  Tyrosin kinase with immunoglobulin-like and EGF-like domain 
Tie1iECKO Tie1 inducible endothelial cells knock out  
Tie1-KO Tie1 global Knock out 
Tie2-KO Tie2 global knock out 
TSP1 Thrombospondin 1 
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U  Unit 
v/v  Volume/Volume 
VE-Cadherin Vascular endothelial cadherin 
VEGF Vascular endothelial growth factor 
VEGFR Vascular endothelial growth fctor receptor 
w/v  Mass Volume (mass concentration) 
WB  Western Blot 
WHO World health organization 
WT Wildtype 
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